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ABSTRACT
Purpose: Oestrogen receptor beta (ERB) has several isoforms which can act as
modulators of ERa. Here ERf isoforms were quantitated in breast cancer patients
andrelated to outcome.
Experimental Design: mRNA of ERI (full-length), C-terminal truncations
(ERB2/ERBcx, ERBS) and exon deletions (ERBAS, ERBA3) were quantitated in 100
cases (70 ERa+ and 30 ERa-). ERB2 immunostaining wascarried out in 141 cases
(98 ERa+ and 43 ERa-). All the breast cancer patients in this study were
postmenopausal womentreated with surgery and adjuvant endocrine therapy, but not
chemotherapyor primary endocrinetherapy.
Results: ERB isoform mRNAs were differentially expressed in ERat+ and ERa-
breast cancers; ERB2 levels were higher whilst, ERB5 and ERB1 levels were lowerin
ERa+ cases. ERB deletion variants were only detected in 20 cancers, mostly ERa-.
In ERa- cases, high ERBS wasassociated with good outcome, independentof nodal
status. In ERa+ cases, high ERB2 mRNA levels were associated with reduced
relapse and improved survival (Log-Rank P=0.01), independent of grade, size or
nodal status (Cox P=0.02). High ERB2 mRNA wasalso associated with better
outcome in the node negative cases (Log Rank P<0.001). High ERB2
immunostaining was associated with better outcome across the whole cohort (Log-
Rank relapse P=0.018), but not in the ERa+ subgroup. There was no clear
association between levels of ERB2 mRNAand protein, but cases with both high
mRNAandprotein had significantly better outcome.
Conclusions: High ERf2 protein levels were associated with ERa expression.
Although most cases with high ERB2 mRNA had strong ERB2 immunostaining,
mRNAlevels but not protein levels were independently predictive of outcome in
tamoxifen-treated ERa+ tumours. Post-transcriptional control needs to be considered
whenassessing the biological or clinical importance of ERB proteins. ERBS mRNA
measurements may beuseful in targeting endocrine therapy in ERa- cases.
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CHAPTER1 INTRODUCTION
1.1 Epidemiology
Breast cancer is the most common cancer in women worldwide accounting for 23%
of all cancers. The incidence is the highest in Europe and North America and lowest
in parts of Asia and Africa, and in between in Eastern Europe, South America and
South Africa (Parkin ef al, 2005). The high incidence in industrialised countries is
thought to be partly due to the early diagnosis of invasive cancers by mammographic
screening programmes. Genetic variations and differencesin lifestyle, including diet
and environmental exposures were thought to play a significant role in the
occurrence of breast cancer in different parts of the world (Dumitrescu & Cotarla,
2005). This concept is supported by the study of migrants from low-risk country to
high-risk countries, which has shownthat the incidence of breast cancer assumes the
rate of the host country within one or two generations (McPhersonet al, 2000).
Breast cancer is the most commoncancer in womenin England. Onein nine women
will develop breast cancer at some point in their lives. Incidence rates for breast
cancer increased by more than 80 percent between 1971 and 2007. The age-
standardized incidence rate increased by 5 percent in the ten years to 2007. The
introduction of national screening programme in the 1988 and the increasing use of
hormonal replacement therapy in the 1990s were thought to have contributed to this
increased incidence. However, mortality rates have fallen by 30 percent since 1971.
Falls occurred in all age groups, but were greatest in women aged 55 to 69 years
(Office for National Statistics, 2009) (Figure 1.1).
1.2 Risk factors
1.2.1 Sex and age
Sex and age are among the strongest risk factors associated with breast cancer.
Breast cancer is mainly a disease of the women.It is 100 times more common in
womenthan men (Thomas, 1993).
Increasing age is an important risk factor for breast cancer as the incidence is very
low before the age of 25 (less than 10 new cases per 100,000 women) and this
increases up to hundred times by the age 45, with four out of every five new cases
are diagnosed in women aged 50 and over (Office For National Statistics, 2009).
This breast cancer risk continues to increase after menopause until age 75 in Western
countries. In contrast, the incidence exhibits a plateau followed by slow decrease in
Japan after 45 years of age (Hulka & Moorman,2001).
1.2.2 Family history
A family history of breast cancer increases the risk of developing the disease. The
risk depends upon the numberofrelatives affected, as well as whetherthey arefirst
degree or second-degreerelatives. A meta-analysis of 52 individual epidemiological
studies showed that compared to women with no family history of breast cancer,
women with one, two and three or morefirst degree relatives had relative risks of 1.8
(99% CI: 1.69 - 1.91), 2.93 (99% CI: 2.36 - 3.64) and 3.90 (CI: 2.03 - 7.49)
respectively (Collaborative Group on Hormonal Factors in Breast Cancer, 2001).
Another meta-analysis showedthat relative risk of having one or more second-degree
relatives was 1.5 (99% CI: 1.4 to 1.6) (Pharoah ef al, 1997). It is also interesting to
note that the Collaborative group meta-analysis has highlighted that eight out of nine
women who develop breast cancer do not have any affected first-degree relatives and
among women, who may have affected first-degree relatives, most will never
develop breast cancer (Collaborative Group on HormonalFactors in Breast Cancer,
2001). This observation supports the notion that most of the breast cancers are
sporadic.
1.2.3 Breast cancer susceptibility genes
BRCAI and BRCA2(breast cancer one and two) are located in chromosome 17 and
13 respectively. These are tumour suppressor genes and mutations in them account
for approximately 80 to 90% of hereditary breast cancers (de Jong et al, 2002). The
cumulative risk of breast cancer in womenis 60% for BRCA 1 mutation carriers and
40% for BRCA 2 mutation carriers (Antoniou ef al, 2003).
Other high penetrance genes implicated in breast cancer include p53, PTEN, ATM
and STK//. The location of these genes in chromosomes and associated syndromes
are summarised in the table (Table 1.1). Mutations in these genes account for 5-10%
of all breast cancers (Oesterreich & Fuqua, 1999).
Recently, a number of genes have raised interest and are thought to play a role in
breast cancer risk. These are called low penetrance cancer susceptibility genes and
they are relatively common. Many encode enzymesof different metabolic pathways.
These genes along with endogenousandlifestyle risk factors may contribute to the
occurrence of sporadic breast cancers, which comprise the majority of all breast
cancers (Johnson-Thompson & Guthrie, 2000). Examples of these genes include
CYPIAI, CYP2D6, CYP19, GSTI and GST Pl, ADHIC, MTHFR, XRCCI and
XRCC3, ERCC4/XPF, ESR1, TNFa and HSP70 (Coutelle et al, 2004; Ergul et al,
2003; Goode et al, 2002; Smith et al, 2003). More recent genome-wideassociation
studies (Easton et al, 2007; Turnbull et al, 2010) have identified further loci
implicated in breast cancer susceptibility including four further plausible genes
(FGFR2, TNRC9, MAP3K1 and LSP1).
1.2.4 Previous breast disease
Atypical epithelial hyperplasia is related to an increased risk of developing breast
cancer. Women whohad severe atypical epithelial hyperplasia have a four to five
times higher risk of developing breast cancer than women who did not have
proliferative changesin their breast. Moreover, the risk of breast cancer increases to
nine times if the woman has an affected first-degree relative in their family
(McPhersonet al, 2000).
1.2.5 Reproductive factors
The reproductive history including the age at menarche, age at first full term
pregnancy as well as number of pregnancies and age at menopause indirectly
provides information about the amount of endogenous sex hormone exposure in
premenopausalyears.
Menarcheat an early age (less than 12 years of age) has been shown to be associated
with 10-25% increased risk of breast cancer compared to women who had menarche
after 12 years of age (Bernstein, 2002; Kelsey et al, 1993). This increased breast
cancerrisk is attributed to prolonged oestrogen and progesterone exposure because
of early onset of menstrual cycles (Bernstein, 2002). Similarly delayed menopauseis
associated with increased risk of breast cancer. Women whohave natural menopause
after 55 years of age are twice as likely to develop breast cancer compared to women
who have menopause before 45 years (McPherson ef al, 2000). In contrast, bilateral
oophorectomy before the age of 35 results in 40% decrease in breast cancer risk,
compared to women experiencing natural menopause (Kreigeref al, 1999).
Women, whohadtheir first baby before the age of 20 had low risk of breast cancer,
compared to women who were pregnant after 30 years of age (MacMahonef al,
1970). It has also has been shown that multiple pregnancies provide a strong
protective effect against breast cancer (Yuan ef al, 1988). Nulliparous women had a
30% increased chance of breast cancer, compared to parous women (Ewertz ef al,
1990; Kelsey et al, 1993). One explanation for the protective effect of childbirth on
breast cancer is that during pregnancy the breast epithelial cells mature and they are
less prone to malignant transformation in the latter years (Gadducci ef al, 2005).
Breast feeding has been postulated to be protective against breast cancer andthere is
4.3% decrease in relative risk of breast cancer for every 12 months of breast feeding
(Collaborative Group on Hormonal Factors in Breast Cancer, 2002). This decrease of
breast cancer risk is thought to be due to reduction in the total number of menstrual
cycles that occur as a result of breast feeding (Bernstein, 2002).
These findings imply that cumulative endogenousoestrogen exposureis a significant
risk factor for breast cancer. At the cellular level oestrogen exerts its effect via
oestrogen receptors. The role of oestrogen receptor alpha (ERa) in breast cancer has
been established, but the importance of oestrogen receptor beta (ER) isstill not
fully understood.
1.2.6 Exogenous hormones
Oral contraceptive use and the risk of breast cancer have been investigated by several
studies. The meta-analysis published by the collaborative group on hormonal factors
showed a significant increase in breast cancer risk in women taking combined oral
contraceptive pills. There was 24% increase in breast cancer risk for current users,
and this risk reduces after stopping pills and disappears at 10 years (Collaborative
Group on Hormonal Factors in Breast Cancer, 1996a; Collaborative Group on
Hormonal Factors in Breast Cancer, 1996b). In contrast, two large studies did not
show association between oral contraceptive pills and increased breast cancer risk
(Hannaford et al, 2007; Marchbankset al, 2002). These inconsistent findings show
that association between oral contraceptive pills and risk of breast cancer, if any, is
likely to be modest.
Hormonalreplacement therapy has been implicated as a risk factor for breast cancer
in postmenopausal women. The risk depends upon the duration of therapy, as well as
whether the therapy contained oestrogen alone or both oestrogen and progestin (Ross
et al, 2000). The risk was higher for oestrogen and progesterone combined therapy
than for the oestrogen only preparations (Santen, 2003). The meta-analysis
conducted by collaborative group on hormonal factors in breast cancer concluded
that HRT users had 14% increased risk of breast cancer, compared to women who
never used it. The risk increased by 2.3% for each year of use for current users.
Increased risk was limited to current or recent use and was not significant for
previous users (Collaborative Group on HormonalFactors in Breast Cancer, 1997).
Despite the increased incidence of breast cancer in women receiving HRT, the
overall mortality among these women is reduced, because there are fewer deaths
related to cardiac disease or osteoporosis (Col et al, 1999; Grodstein et al, 1997).
1.2.7 Lifestyle factors
Epidemiological studies have shown association between alcohol intake and
increased risk of breast cancer (Longnecker, 1994; Longneckeret al, 1995). The risk
increases linearly in a dose-dependent manner. There was no apparent increase in
breast cancer risk in women whodrank less than one standard unit per day, compared
to non-drinkers. However, the relative risk of breast cancer increased by 7% for
every additional standard drink of alcohol (i.e. ~10 g of alcohol per day) (Hamajima
et al, 2002).
The association between high fat intake and breast cancer risk is controversial. The
majority of cohort studies have failed to find an association between dietary fat
intake and breast cancer risk (Hunter ef al, 1996; Willett et al, 1992). However, a
recent pooled analysis suggests that high intakeof saturated fat increases the breast
cancerrisk (Smith-Warneref al, 2001).
Obesity has a complex relationship with breast cancer risk. In postmenopausal
women,obesity is associated with increased breast cancer risk, and in premenopausal
women there is decrease in breast cancer risk (Cleary & Maihle, 1997; Huangetal,
1997; Potischmanet al, 1996; Trentham-Dietz et al, 1997). The possible explanation
is that obese postmenopausal woman may have low serum concentration of sex
hormonebinding globulin and high serum concentration of the oestrogen leading to
increased risk of breast cancer (Thomasef al, 1997). However, premenopausal obese
women are more likely to have anovulatory cycles and longer menstrual cycles,
resulting in less cumulative oestrogen exposure and reduced breast cancer risk
(Hendersonef al, 1985).
1.3 Prognostic and predictive factors
A prognostic factor is any measurement available at the time of surgery that
correlates with disease-free or overall survival in the absence of systemic adjuvant
therapy and, as a result, is able to correlate with the natural history of the disease. In
contrast, a predictive factor is the measurement associated with response to a given
therapy (Cianfrocca & Goldstein, 2004).
1.3.1 Histological type
Breast cancer is classified into various histopathologic types depending upon
microscopic morphology. Invasive ductal carcinoma of no special type (NST)
accounts for 70 to 80% of breast cancers. The next commonbreast cancer is invasive
lobular carcinomaaccounting for 5 to 10% of breast cancers. Even though they have
some differing disease pattern, a study by Sastre-Garau ef al. has shown that both
ductal and lobular carcinoma had similar prognosis in terms of disease-free and
overall survival (Sastre-Garau et al, 1996).
Tubular, papillary, medullary and mucinous cancers are other rare varieties, and
these cancers have better prognosis than invasive ductal and lobular carcinoma
(Cianfrocca & Goldstein, 2004). Another rare type is inflammatory breast cancer.
This is an aggressive form of breast cancer and the patients are youngerat diagnosis
and have worse prognosis compared to other types (Changet al, 1998).
1.3.2 Tumoursize
Tumoursize is one of the strongest prognostic factors along with axillary lymph
node status (Vorgias ef al, 2001). Larger tumours were associated with more positive
nodes (Weiss ef al, 2003). In lymph node negative patients, tumour size helps to
make decisions about adjuvant treatment options (Cianfrocca & Goldstein, 2004).
Carter et al. analysed over 13000 node negative breast cancer patients from the
SEER database (Surveillance, Epidemiology, and End Results data of the National
Cancer Institute). Tumour size was categorised into three groups and survival
analysis calculated. The overall survival was close to 99% for tumours less than 1 cm
in size and 89% for tumours between | to 3 cm in size and 86% for tumours between
3 to 5cm (Carteret al, 1989).
1.3.3 Histological grade
Breast cancers are graded using Scarff-Bloom-Richardson classification. According
to the classification, tumours are classified into well differentiated, moderately
differentiated and poorly differentiated cancers. Well differentiated cancers were
associated with better prognosis (Bloom & Richardson, 1957). Tumour grade is
mainly useful to make adjuvant treatment decisions in node-negative cancers with
borderline tumoursizes (Cianfrocca & Goldstein, 2004).
1.3.4 Lymphovascularinvasion
Lymphovascular invasion is the presence of neoplastic cells within the
lymphovascular space in the peritumoural tissues. Rosen ef al. have shown
correlation between lymphovascular invasion and disease recurrence.In this study of
461 patients with stage one breast cancer, at 20 year follow-up lymphovascular
positivity was associated with significantly higher disease recurrence (Rosen efal,
1989). In another study of 1275 patients, lymphovascular invasion was associated
with 15% increase in disease recurrence at 5 years of follow-up and this effect was
independent of whetheror not they received adjuvant treatment (Neville ef al, 1992).
1.3.5 Axillary lymph nodestatus
The single most important prognostic factor for breast canceris axillary node status.
Node positive patients had much worse prognosis compared to node negative
patients (Arriagada ef al, 2006; Fisher et al, 2001). The number of positive nodes
directly correlates with worse prognosis. In a study of node positive breast cancer
patients, who were treated with chemotherapy and followed up for 20 years, the
median disease free survival was 11.1 years for the patients with one to three nodes,
5.4 years for the patients with four to nine nodes, and 2.1 years for the patients with
10 or more positive nodes (Weissef al, 2003).
1.3.6 ER/PRstatus
Oestrogen and progesterone receptor status serve as both prognostic and predictive
factor. ER positive cancers had better relapse free survival than ER negative breast
cancers (Fisher et al, 1988; Knight et al, 1977). However, this survival benefit was
not maintained in other long term follow-up studies (Andry ef al, 1989; Hilsenbeck
et al, 1998; Raemaekerset al, 1985).
ER and PR status are powerful predictive factors for hormone therapy with
tamoxifen (Early Breast Cancer Trialists' Collaborative Group, 1998) and aromatase
inhibitors (Baum ef al, 2002; Thurlimann et al, 2005). However, not all hormone
receptor positive patients respond to anti-oestrogens; approximately 25% of
ER+/PR+, 66% of ER+/PR-, and 55% of ER-/PR+ breast tumoursfail to respond to
anti-oestrogens (Honig SF, 1996). The mechanism of resistance is not fully
understood and is an area of intense research and will be discussedlater.
1.3.7 HER? status
HER2, also known as c-erbB2 is a member of the epidermal growth factor family
with tyrosine kinase activity (King ef al, 1985). It is amplified and overexpressed in
15%-30% of breast cancers (Slamon ef al, 1987), although recent rates reported by
standardized reporting in the UK are 15-17% (Walker ef al, 2008), and the
expression is associated with poor prognosis (Esteva & Hortobagyi, 2004).
Currently, HER2 testing is part of a routine pathological workup in all newly
diagnosed breast cancer patients (Wolff et al, 2007). HER2 expression is inversely
correlated with ER/PR status and in one series it was expressed in 7% of
postmenopausal patients who were ER positive (Rasmussen ef al, 2008). HER2 is
also a predictive marker for treatment with monoclonal antibody trastuzumab.
Combination of trastuzumab and chemotherapy in breast cancer patients resulted in
better relapse free and overall survival in the metastatic (Slamonef a/, 2001) as well
as in the adjuvant treatmentsetting (Pritchard ef al, 2006).
1.3.8 Gene expression profile
Gene expression profiling is a new technology, which is revolutionising the
understanding of various cancers. Using this microarray technology, the expression
of thousands of genes can be measured in each sample and molecular patterns can be
identified through bioinformatics analysis. In breast cancer, molecular profiling has
identified molecular subtypes (Luminal A, Luminal B, HER2+ and Basal-like) that
reflect intrinsic properties of the tumours (Sorlie et al, 2001) and expression patterns
that are highly correlated with patient outcome (Sorlie ef a/, 2001; van 't Veer ef al,
2002).
Oncotype DX and other gene expression studies like the Mamma Print assay
(Agendia BV, Amsterdam, the Netherlands), Rotterdam Signature, and the Breast
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Cancer Gene Expression Ratio may aid in accurately assessing prognosis as well as
in allocating various treatment modalities to breast cancerpatients.
For example, Oncotype DX (Genomic Health Inc., Redwoodcity, CA) measures the
expression of 21 genes at the mRNA level in formalin-fixed paraffin embedded
specimens and a “recurrence score” is calculated from this. The genes measured
represent pathways including oestrogen (e.g. ER and PgR), proliferation (e.g. Ki67
and cyclin B), invasion (e.g. Stromelysin 3 and Cathepsin L2) and HER2. Each gene
group is weighted to produce a combinedrecurrence score (0-100). This score is then
divided into low, intermediate and high risk score that is used to plan treatment. Paik
et al. validated this multi-gene assay in a cohort of 668 patients, who were node-
negative, ER positive and tamoxifen treated, and enrolled in the NSABP-B14 trial.
The 10-year distant recurrence rate was 6.8% in patients with low score, 14.3% for
patients with intermediate score and 30.5% for patients with high score (P<0.001).
The recurrence score was independent of age and tumour size in multivariate
analysis (Paik et al, 2004). Similar results were also observed in a large population
based study (Habel et al, 2006). Oncotype DX recurrence score was also able to
identify patients, who may benefit from chemotherapy in a cohort of node-negative,
ER positive and tamoxifen treated patients (Paik et al, 2006). This may be very
useful in clinical setting to select patients for chemotherapy who are node negative
and ER positive.
1.4 Hormonal manipulation
1.4.1 Ovarian suppression
In 1896, George Beatson, a surgeon from Glasgow showed that oophorectomy in
premenopausal womenresulted in breast cancer regression and improved prognosis;
however, it benefited only onethird of patients (Beatson, 1986). This was theearliest
demonstrated link between breast cancer and ovarian hormones. Early endocrine
therapy also included adrenalectomy and hypophysectomy, but they were later
abandoned when tamoxifen was introduced in the treatment of advanced breast
cancer in 1978 (Strasser-Weippl & Goss, 2005). A meta-analysis by EBCTCG
showed that in women, aged under 50 with early breast cancer, ablation of
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functioning ovaries significantly improves long-term survival (Early Breast Cancer
Trialist's Collaborative Group, 1996). Ovarian suppression still remains as an
important anti-hormonal treatment in premenopausalbreast cancer patients. Ovarian
suppression with LHRH agonist (e.g. goserelin) produces serum oestrogen and
progesterone level similar to levels in women who have undergone oophorectomy
(Pinder & Buzdar, 2008). In a trial comparing goserelin with chemotherapy, at a
median follow-up of 7 years goserelin was similar to chemotherapy in terms of
disease-free and overall survival in pre/peri-menopausal women who were ER
positive and node positive (Kaufmann ef al, 2003). In another trial comparing
goserelin with tamoxifen to CMF chemotherapy, at median follow-up offive years,
the combination of goserelin and tamoxifen were better in terms of disease-free
survival in ER positive premenopausal woman (Jakesz ef al, 2002). Another
international study compared CMF on its own, goserelin on its own, and CMF
followed by 18 months of goserelin. The patients treated with both goserelin and
CMFchemotherapy had a better five-year overall survival than the other two groups
in ER positive patients, and the benefit was significantly higher in young patients
whoare less than 40 yrs old (Castiglione-Gertsch et al, 2003).
1.4.2 Anti-oestrogens
In 1936, Professor Antoine Lacassagne proposed that breast cancer could be
prevented by drugs that antagonise the effects of oestrogen (Lacassagne, 1936). In
1958, the first non-steroidal oestrogen antagonist 1-(p-2-diethylaminoethoxyphenyl)-
1-phenyl-2-p-methoxypheny] ethanol (MER-25) was discovered (Lerneref al, 1958),
but in clinicaltrials, it showed low potency and high central nervous system toxicity
(Herbst et al, 1964).
Tamoxifen
Tamoxifen is a trans isomerofsubstituted triphenylethylenes (ICI 46,474) and it was
initially developed as an oral contraceptive, but found to have potential anti-
oestrogenic action (Harper & Walpole, 1966). In 1960s oestrogen receptor was
identified (Jensen, 1962), and tamoxifen was found to block oestrogen binding to
oestrogen receptor (Jordan & Koerner, 1975). In a prospective trial of ER and PR
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positive patients who had advanced breast cancer, 70% of patients responded to
tamoxifen treatment, and in patients who were ER/PRnegative the response rate was
less than 10% (Ravdinef al, 1992). Tamoxifen wasas effective as diethylstilbestrol
in the management of metastatic breast cancer (Gockermanef al, 1986). Following
these trials in metastatic and advanced breast cancer settings, tamoxifen was
approved to treat patients in the adjuvant setting. An overview of 55 randomized
trials showed that five years of tamoxifen therapy reduced breast cancer recurrence
by 42% and mortality by 22% at 10 years (Early breast Cancer Trialist's
Collaborative Group, 1998). Tamoxifen treatment for five years became the standard
duration of therapy, as more than five years did not show anyfurther improvementin
disease-free survival or overall survival (Fisher et al, 1996; Tormey et al, 1996).
Tamoxifenis still one of the first line hormone therapies in both premenopausal and
postmenopausal women with breast cancer. Five years of tamoxifen therapy also
reduced contralateral breast cancer by 47% (Early breast Cancer Trialist's
Collaborative Group, 1998). Tamoxifen also reduced the frequency of invasive
breast cancer and DCIS by about 50% in high-risk women in the NSABP
chemopreventiontrial (Fisher et al, 1998).
Tamoxifen is a mixed agonist and antagonist; it is beneficial in terms of reducing
cholesterol concentrations, preserving bone density and reducingthe risk of fractures
in postmenopausal women. However, there are increased risk of endometrial cancer
and thrombosis (O'Regan & Jordan, 2002).
Fulvestrant
Fulvestrant (ICI182,780) is a pure steroidal anti-oestrogen with none of the agonistic
properties found in other selective oestrogen receptor modulators (Wakeling efal,
1991). Fulvestrant not only blocks ERreceptor, it also induces ER degradation with a
marked reduction in the cellular concentration of ER (Osborneet a/, 2000). In animal
models fulvestrant has been shown to be a more potent inhibitor of tumourigenesis
and also produces regression of established tumours (Osborne ef al, 1995). In a
double-blind randomized multicentre trial, fulvestrant was as effective as tamoxifen
as a first-line endocrine therapy in metastatic or locally advanced breast cancer
patients (Howell et al, 2004). Additionally fulvestrant was beneficial as secondline
endocrine therapy in advanced breast cancer patients who develop resistance to
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tamoxifen (Howell et al, 1995). In a double-blind randomizedtrial, the efficacy and
tolerability of fulvestrant was compared with anastrozole in postmenopausal women
with advanced breast cancer progressing on prior endocrine therapy, fulvestrant was
as effective as anastrazole (Osborne ef al, 2002) and the same effect was seen in
another randomized controlled trial (Howell et al, 2002). These data confirm that
fulvestrant is an additional, effective, and well-tolerated treatment for advanced
breast cancer in postmenopausal women whose disease progressed on prior
endocrine therapy.
1.4.3 Aromatase inhibitors
Aromataseinhibitors (AIs), especially the newer generation are an important addition
to endocrine therapy in breast cancer. They inhibit the enzyme aromatase, which
belongs to cytochrome P-450 superfamily and encoded by CYP/9 gene (Evansetal,
1986), hence reducing the production of oestrogen. Aromatase enzymeis present in
subcutaneousfat, liver, muscle, brain, bone, normal breast and breast cancer tissue
(Nelson & Bulun, 2001). The first generation Als (e.g. aminoglutethimide) non-
selectively block the enzymes of cytochrome 450 resulting in adrenal suppression as
well. Because of this mechanism of action, aminoglutethimide had to be given with
high-dose corticosteroids and also caused serious side effects (Howell & Buzdar,
2005). The second generation formestane wasthe first selective AI, but it had short
half life and had to be given as an intramuscular injection (Pinder & Buzdar, 2008).
The third generation Als (anastrozole, letrozole and exemestane) selectively block
aromatase and are widely used in endocrine treatment of breast cancer. Anastrozole
and letrozole are non-steroidal inhibitors and competitively block aromatase in
reversible manner (Vanden Bosscheef al, 1994). On the other hand, exemestane is a
steroidal inhibitor, it blocks aromatase irreversibly and is also known assuicidal
inhibitor (Brueggemeier, 1994). In postmenopausal women, AIs suppress the
circulating oestrogen level by over 95% (Demers, 1994; Geisler et al, 2002). In
addition, Als have the potential to block the oestrogen production by the
peritumoural breast cancertissue (Santen ef al, 1999). Als are mainly used in women
with no ovarian function, i.e. postmenopausal women, as in women with intact
ovarian function it causes a rise in gonadotrophin releasing hormonelevels, with
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resultant increases in oestrogen production (Pinder &Buzdar, 2008). So, Als are
contraindicated in premenopausal women with intact ovarian function (Smith &
Dowsett, 2003).
Anastrozole
Anastrozole is a non-steroidal selective competitive aromatase inhibitor. It is
administered orally and peak serum concentration is reached within two hours, with a
plasma half-life of 30-60 hours (Plourde et al, 1994). In a combined analysis of two
randomized controlled trials comparing anastrozole with megestrol acetate (a
progesterone derivative used in the treatment of metastatic breast cancer) in women
with advanced breast cancer who failed on tamoxifen, survival was significantly
longer for patients treated with anastrozole with fewer side effects (Buzdar ef al,
1998). Anastrozole was also shown to be beneficial in metastatic breast cancer in
postmenopausal women, compared to tamoxifen as a first-line hormone therapy
(Bonneterre et al, 2000). Anastrozole was then evaluated in early breast cancer as
first line therapy. In the ATACtrial (Arimidex, Tamoxifen Alone or in Combination
Trial) 9366 women were randomized to 5 years of tamoxifen, anastrozole or a
combination of both therapies. After 68 months of median follow-up anastrozole
significantly prolonged disease-free survival and time to recurrence, and there was
also significant reduction in occurrence of distant metastases and contralateral breast
cancer. In this trial, tamoxifen caused fewer musculoskeletal complaints and
fractures, but wasless tolerated with respect to endometrial cancer, vaginal bleeding
and thromboembolic events. The authors concluded that anastrozole should be
considered as the first line hormonal therapy in postmenopausal hormone positive
breast cancer patients (Howell ef al, 2005).
Letrozole
Letrozole is the other non-steroidal competitive aromatase inhibitor. It is more potent
than anastrozole in suppressing aromatase enzyme (Santen & Harvey, 1999). Onoral
administration it is absorbed rapidly and reaches steady-state plasma concentrations
in 4-8 hours andits half-life is approximately 45 hours (Mitwally & Casper, 2001).
It was initially evaluated in advanced breast cancer treatment as a second-line
endocrine treatment. In one European study, letrozole was superior to
aminoglutethimide (Gershanovichef al, 1998) in disease control in post menopausal
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women in advanced breast cancer. In another study letrozole was more effective and
better tolerated than megestrol acetate in the treatment of postmenopausal women
with advanced breast cancer previously treated with anti-oestrogens (Dombernowsky
et al, 1998). Letrozole was superior to tamoxifen asfirst-line endocrine treatment in
metastatic breast cancer (Mouridsen ef al, 2003). The Breast International Group
(BIG) 1-98 trial compared letrozole and tamoxifen as adjuvant treatment in
postmenopausal women with hormonereceptor positive early breast cancer. Women
were randomly assigned to receive: tamoxifen alone for five years; letrozole alone
for five years; tamoxifen for two years followed by letrozole for three years; and
letrozole for two years, followed by tamoxifen for three years. At 76 months of
median follow-up the letrozole arm showedbetter disease-free survival compared to
tamoxifen, but there was no significant overall survival benefit (Coates et al, 2007).
There was no significant benefit compared to upfront letrozole to sequential
treatment with letrozole and tamoxifen (Mouridsen ef al, 2009). Patients on
tamoxifen experienced more thromboembolic events, endometrial pathology, hot
flashes, night sweats, and vaginal bleeding, whilst patients on letrozole experienced
more bone fractures, arthralgia, low-grade hypercholesterolemia and cardiovascular
events (Coates et al, 2007). Another trial MA.17 looked into extended adjuvant
therapy. Patients were randomized to letrozole or placebo after five years of
tamoxifen therapy. This trial was stopped early as letrozole showed significantly
improved disease-free survival. Although there was nooverall survival advantage in
the whole cohort, there was significantly improved overall survival in node positive
patients (Goss et al, 2005).
Exemestane
Exemestaneis an orally active, steroidal, irreversible aromatase inhibitor (di Salle et
al, 1992). Its half life is 24 hours, comparatively less than that of non-steroidal
inhibitors (Brueggemeier, 2002). In a randomized multicentre study (Kaufmannet al,
2000) exemestane was compared with megestrol acetate as a secondline therapy in
postmenopausal women with advanced breast cancer who were previously treated
with tamoxifen. Time to progression, time to treatment failure and overall survival
were better in the exemestane arm andit was also well tolerated. Another phase III
randomized open-label clinicaltrial evaluated the efficacy and safety of exemestane
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with tamoxifenasfirst-line treatment for metastatic breast cancer in postmenopausal
women. There was better median progression-free survival in the exemestane arm,
but there was no overall survival benefit (Paridaens et al, 2008). The Intergroup
Exemestane Study (IES) compared tamoxifen for 5 years to tamoxifen for 2 to 3
years followed by exemestane for a total of five years of endocrine therapy in
hormonepositive early breast cancer patients. There was better disease-free survival
at a median follow-up of 55 months as well as a non-significant reduction in death in
the exemestane group (Coombesef al, 2007).
1.5 Oestrogen receptors in breast cancer
1.5.1 Oestrogen receptor alpha (ERa)
In 1950s, Jensen and Jacobson demonstrated that oestradiol was specifically retained
by oestrogen target tissues and proposed that a receptor should exist for oestrogen
(Jensen & Jacobson, 1962). After some years, oestrogen receptor wasidentified (Toft
& Gorski, 1966) and it was eventually cloned in 1980s (Greeneet al, 1986; Walter et
al, 1985). The oestrogen receptor gene (now named ESR/) was foundto be localised
at chromosome 6q24-27 (Gosden ef al, 1986; Ponglikitmongkol et al, 1988).
Oestrogen receptor structure is similar to other nuclear receptor super family
members (Green ef al, 1986). It has six structural domains (domains A-F) and
defined functional domains (Figure 1.2). The transactivation function domain AF-1
is located within the amino-terminal A and B domainsandit is ligand independent
(Kumar eft al, 1987; Ribeiro et al, 1995). The C domain contains a DNA binding
domain that is responsible for binding to specific oestrogen response elements (ERE)
within the promoters of the oestrogen responsive genes (Klein-Hitpasset al, 1988). C
and E domains contain the oestrogen receptor dimerization domain (Ribeiro ef al,
1995). The carboxy terminal E andF are the ligand binding domain and contains the
ligand dependant transactivation domain AF-2 (Norris ef al, 1997). The ligand
independent domain AF-1 can be activated by cAMP, dopamine, and growth factor
receptors epidermal growth factor (EGF) and Insulin like growth factor 1 (IGF-1)
(Herynk & Fuqua, 2004). This multi-domain structure allows oestrogen receptors to
process multiple signals (e.g. oestrogen, growth factors), integrate them via cross
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talk, and produce individualised responses (via ERE and/or SP1/AP1 promoter
elements) (Figure 1.3). Several coregulatory proteins act as intermediary factors,
which augment or suppress oestrogen receptor transactivation (Rosenfeld & Glass,
2001). These coregulators contribute to tissue specific actions of ERs, as they are
expressed differentially in different cell types and tissues.
Gene splicing is a post-transcriptional modification due to differential inclusion or
exclusion of exonsresulting in multiple proteins (Black, 2003). Althoughsplicingis
a normal phenomenon it has been implicated in various diseases and cancers
(Venables, 2004). ERa splice variants (mainly exon deletion variants) were identified
in many normal tissues as well as in breast cancers (Herynk & Fuqua, 2004; Poola &
Speirs, 2001). Most of the variants are transcriptionally inactive and some (ERaA3
and ERaA7) showed dominant negative activity to wild-type ERa (Garcia Pedrero et
al, 2003; Wang & Miksicek, 1991). ERa splice variants were thought to play a role
in tumourigenesis and response to various anti-cancer treatments (Poola & Speirs,
2001), however, as the splice variants were expressedin relatively few cancers and in
relatively low levels compared to wild-type ERa the exact significance is unknown
(Zhanget al, 1996).
Oestrogen receptor, present in 40-70% of breast cancers, is an independent
prognostic marker (Knight ef al, 1977) and also predicts response to endocrine
therapy in breast cancer (Pertschuk & Axiotis, 1999). Anti-oestrogen strategies, such
as inhibition of oestrogen-receptor binding and oestrogen deprivation, are effective
for the management of hormone-dependent breast cancer (Brueggemeier, 2002), but
up to 40% of tumours fail to respond to endocrine therapy (McGuire, 1975). The
mechanism of this resistance is poorly understood. With the discovery of second
oestrogen receptor in the 1990s there is huge interest in evaluating its role in
hormoneresponsiveness.
1.5.2 Oestrogen receptor beta (ERB)
In the 1990s, a second oestrogen receptor, named as ERf (the classic oestrogen
receptor being renamed ERa), was identified in a rat prostate cDNA library andit
encoded a protein of 485 amino acids (Kuiperef al, 1996). ERB was also found in
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mouse (Tremblay ef al, 1997) and human (Mosselmanef a/, 1996). Further studies
identified a longer 530 amino acid sequence (Moore et al, 1998; Ogawaet al, 1998a)
and this was universally accepted as the full length ERB. ERB was localised to
chromosome 14q22-25 (Enmarkef al, 1997). Like ERa, ERB resides in cytoplasm
and translocates to nucleus after ligand binding (Leung ef al, 2006). The ERB has
structural domainssimilar to other nuclear receptor super family members,especially
ERa, and has a high degree of homology with ERa in certain areas. There is 96%
homology in the DNA binding domain and 53% homology in the ligand binding
domain (Figure 1.2) (Weihuaef al, 2003). There is less conservation between these
two receptors in the amino terminal AF-1 and carboxy terminal AF-2, suggesting
there may be functional differences.
ERa and ERBare differentially expressed in breast and other tissues (Kuiperef al,
1997; Saunders et al, 1997). One study (Taylor & Al-Azzawi, 2000) looked at ERa
and ERB in a whole range of normal tissues in human. This study showedthat
distribution of ERB appeared to present with ERa in mosttissues, however ERB did
not appear to be linked with ERa expression as some ERa positive cells lack ERB
and vice versa. For example, prostate only expressed ERB and liver only expressed
ERa. In normal breast, ERa is only present in luminal epithelial tissues (Petersen ef
al, 1987) and is sparsely expressed (Clarke et al, 1997; Ricketts et al, 1991). In
contrast, ERB is widely expressed in normal breast and apart from epithelial cells
also expressed in myoepithelial cells, stromal cells and endothelial cells (Palmieri e¢
al, 2002; Speirs et al, 2002). However, the level of ERB mRNA is much lowerthan
ERa in breast cancers (de Cremoux et al, 2002; Speirs et al, 1999a).
1.5.3 Splice variants of ERB
Manysplice variants (exon deletion, insertions and c-terminal variants) of ERB have
been identified (Poola et al, 2002a; Poola & Speirs, 2001). Deletion variants are of
unknown functional significance as it is unclear whether they are expressed as
proteins or not. One variant, ERBAS is detected in normal breast (Speirs et al, 2000)
and in breast cancers (Poola et al, 2002b; Vladusic ef al, 1998). ERBAS lacks
hormone binding and shows dominantnegative activity towards both ERa and ERB
(Herynk & Fuqua, 2004). Poola ef al. investigated ten ERB exon deletion variants in
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43 breast cancers and matched normaltissues by semi-quantitative RT-PCR. ERBAS-
6 variant expression wassignificantly less in cancer tissues. ERBAS expression was
associated with postmenopausal status and tumour grade. ERBA2 and ERBA4 were
expressed at low levels and ERBA7 was not detected (Poola et al, 2002b). ERBA3
was originally identified in ovary and has not been identified in normal breast or
cancer (Poola ef al, 2002b) but it is thought to encode part of the DNA binding
domain and the assumption is that it may play a role with other transcription factors
and further study has been recommended (Herynk & Fuqua, 2004).
The C-terminal splice variants are ERB2, ERB3, ERB4 and ERB5. The wild type was
renamed as ER#$1. All five isoforms diverge at a common position within the
predicted helix 10 of the ligand binding domain of ERB, with nucleotide sequences
consistent with differential exon usage (Moore ef al, 1998) (Figure 1.2). These
variants/isoforms are commonly known as C-terminal variants. ERB2, ERB4 and
ERBS like ERB1, are expressed in many normal tissues and breast cancers (Chiet al,
2003; Girault et al, 2004; Scobie ef al, 2002). ERB3 was thoughtto betestis specific
but has been detected in low amount by qRT-PCR in normal and malignant breast
(Chi et al, 2003; Girault et al, 2004). However, these variants are expressed
differentially in many normaltissues (Mooreef al, 1998). In breast, ERB1, ERB2 and
ERBS were the three major isoforms in both normal and tumoural breast tissue
(Girault et al, 2004). Within breast these isoforms are differentially expressed, while
ERB2 is less expressed, ERBland ERB5 are predominantly expressed in terminal
ductal lobular unit and luminal epithelial cells, respectively (Speirs & Shaaban,
2009).
ERB1 binds oestradiol with high affinity and in transient transfection studies ERB
activates transcription in oestrogen-dependent manner (Hanstein ef al, 1999). ERB1
also forms heterodimers with ERa (Cowley ef al, 1997). ERB2 is also known as
ERfcx and has a unique c-terminus with exon 8 replaced by an alternative exon of
26 amino acids (Ogawaet al, 1998b). The ERB2 forms non-functional heterodimers
with ERa and functions as a dominant negative inhibitor (Zhao et al, 2007). In in
vitro analysis, ERB2 has been found to be more expressed in the cytoplasm than in
the nucleus and is modulated by 17B-oestradiol (Al-Madhouner al, 2007). ERB4 and
ERB5, like ERB2 can also form heterodimers with ERa and negatively regulate
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transcription (Poola et al, 2005a). The functional role of ER®3 is unclear as it is
expressed at very low levels and has been investigated less. It was thought that ERB
isoforms can form heterodimers with each other (Moore et al, 1998). However,
recently through molecular modelling Leung et al. showed that ERB1 is the only
functional isoform and that ERB2, ERB4 and ERB5 do not have innate activities in
their homodimeric forms but can heterodimerize with ERB1 and enhance ERf1
induced transcription in ligand-dependent manner (Leung eft al, 2006). This has
functional significance in individual tissues as these variants are differentially
expressed.
1.5.4 Oestrogen receptor B in breast cancer
ERB is the dominant receptor in normal breast and unlike ERais also expressed in
myoepithelial cells, stromal cells and fibroblasts. In contrast to ERa there is no
difference in expression level of ERB during the menstrual cycle (Shaw ef al, 2002).
ER® is anti-proliferative; when reintroduced into breast cancer cell lines it caused
cell-cycle arrest. It caused tumour regression in a xenograft model (Paruthiyil et al,
2004). ERB shows features of tumour suppressive effects; lowered levels are
associated with malignant progression in breast (Bardin et al, 2004; Shaaban efal,
2003; Skliris et al, 2003). However, over 75% of breast cancers express ERf,
compared to the 85% of the normal breast (Shaw ef al, 2002) but ERB expressionis
significantly lower in breast cancer, compared to normalbreast tissue (Girault et al,
2004; Iwao et al, 2000; Leygue et al, 1998), supporting the theory that ERB
expression is reduced/lost in tumourigenesis. Earlier studies looking at the role of
ERB in breast cancer at the mRNA level were inconsistent with each other (as
reviewed elsewhere) (Speirs et al, 2004). However, many used non specific primers
which may detect multiple C-terminal variants that have differing functional
activities (Davies ef al, 2004). Levels of ERB2 and ERB5 mRNAare recognised to be
higher than those of the ERB1 variant (Iwao et al, 2000; Leygue et al, 1999); hence,
many of the non-specific RT-PCR studies may have measured these variants in
varying amounts depending upon the primer selection and PCR methodologies,
contributing to the inconsistencies in the reported findings. With the availability of
the ERB antibodies. protein studies by immunohistochemistry was utilised. ERB
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mRNAlevel did not correlate with protein expression in many comparative studies
(O'Neill et al, 2004; Omoto et al, 2002; Shaw et al, 2002). This may be partly due to
measurement of non-tumoural expression of ERB by PCR techniques. Another
explanation may be that multiple splice variants that were not translated in to
proteins were inadvently measured by PCR using nonspecific primers. The
antibodies may also have had differing specificities.
The majority of ERB protein studies have not found correlations with standard
clinicopathological markers (Esslimani-Sahla et al, 2004; Palmieri ef al, 2004;
Skliris et al, 2006). However, some studies have shown somecorrelation. Saji et al.
showed correlation between ERB2 and PgR negative status (Saji et al, 2002). Chi et
al. showed association between ERB3 and ERB5 with large tumourin a small study
of 17 patients (Chi et a/, 2003). Skliris ef al. found correlation between ERB and
ERa/PgR status (Skliris et al, 2003). There were studies that measured outcome in
association with ERP but again these studies looked at either total ERB or individual
isoforms. In a recent large population based study (Nurse’s Health Study) ERB1
expression was assessed in women whodeveloped breast cancer (2170 cancers) and
correlations were sought between molecular subtypes of breast cancer. ERf1
expression wassignificantly related to molecular subtypes and was more common in
luminal A (73%) and luminal B (68%) than in HER2 orbasal-like types. However,
ERB1 expression was found in 55% of HER2 type and 60% of basal-like subtypes
(Marotti et al, 2010). This large population-based study is of great importanceasit
has clearly shown association between ERfpositivity and good prognostic molecular
subtypes. Moreover, it also shows that ERB can be expressed in aggressive molecular
subtypes suggesting that there may be other explanations for this differential
expression.
Total ERB wasassociated with improved outcomein two studies (Mann ef al, 2001;
Murphyef al, 2002) whilst in another Greek study it was not (Stefanou ef al, 2004).
High ERB1 protein expression has been associated with better outcome (Myersetal,
2004; Nakopoulou ef al, 2004; Omoto et al, 2001). One large study looked at ERB1
in a cohort of 728 patients, in node negative cases ERB1 expression was found to be
associated with better outcome; however, in the node positive group ERB1 was
associated with worse outcome (Novelli et a/, 2008). There wasnocorrelation with
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ERB1 and outcomein a cohort (ERa+/ERa-) of 167 patients (O'Neill et al, 2004) and
also no correlation was seen for both ERB1 and ERB2 in a ERa negative cohort (255
patients) (Skliris et al, 2006).
Since this study has been completed others (Honmaet al, 2008; Shaabanefal, 2008;
Sugiura et al, 2007) have published concerning the role of ERB variants (especially
ERB2)in larger cohorts and they are discussedin the later chapters.
The majority of the studies discussed here show that ERB wasassociated with good
outcomeandit was not associated with standard clinicopathological parameters. This
contradiction means that ERB may be valuable in terms of identifying aggressive or
indolent cancers not picked up by standard markers.
1.5.5 ERs and tamoxifen in oestrogen signalling
Oestrogen exerts its biological effects through at least four pathways (Figure1.3). In
the first pathway (classical ligand dependant) oestrogen (E2) binds to ERs and forms
homo or heterodimers depending upon the receptor content. /n vitro studies have
shown that when coexpressed ERa and ERpreferentially form heterodimers
(Cowley et al, 1997). Thus it has been proposed that in cells coexpressing both
receptors overall oestrogen responsiveness may be determined by the ERa:ER®ratio
(Hall & McDonnell, 1999). ERB2 also preferentially heterodimerize and inhibit ERa
activity suggesting a modulatory role for ERB (Ogawa ef al, 1998b). After
dimerization, the E2-ER complex recruits coactivator proteins and binds to oestrogen
response elements (ERE) in promoters of target genes and activates transcription and
subsequent tissue responses. In contrast, tamoxifen recruits corepressors and inhibits
transcription (Shang ef al, 2000). Coregulatory proteins (either coactivators or
corepressors) are recruited depending upon the promoterstructure, cell type, type of
ligand and type of receptor subtype (Klinge, 2000).
In the second pathway (ERE independent) the E2-ER complex can activate
transcription by tethering to alternative response elements such as those for
Activator Protein 1 (AP-1) through Jun/Fos-proteins (Kushner et a/, 2000) and can
also activate transcription via Specificity Protein 1 (SP-1) (Saville et al, 2000).
However, ERa and ERB behave in opposite manners in this pathway; E2 activates
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transcription via ERa while ER inhibits transcription. Moreover, tamoxifen
activates transcription via ERB (Paechef al, 1997).
In the third pathway (ligand independent) growth factors (EGF/IGF-1) or cyclic
adenosine monophosphate (c-AMP) activate intra cellular kinase pathways, leading
to phosphorylation and activation of ER at ERE containing promoters in a ligand
independent manner. This pathway may play a role in mitogenesis within ER
positive tissues (Hallet al, 2001).
In the fourth pathway [MembraneInitiated Steroid Signalling (MISS) - previously
termed non-genomic signalling], E2 activates a putative membrane-associated
binding site, possibly a form of ER linked to intracellular growth factor signalling
pathwaysthat generate rapid tissue responses (Loselef al, 2003). Recent studies have
shown membrane ERa and ERB accounting for 5% of total ER content (Levin, 2001;
Razandi et al, 2003). However, the studies were mainly done in pituitary and blood
vessels, a role for membrane-bound ER in breast has not been fully elucidated
(Speirs & Walker, 2007). MISS can be activated by both E2 and tamoxifen
(Massarweh & Schiff, 2007). Recently, GRP30, a non-ER protein wasidentified in
the plasma membrane.It is a G protein coupled seven transmembrane receptor and
has been thought to play a role in mediating MISS (Thomasef al, 2005). However
the exact role of MISSisstill unclear in breast cancer (Speirs & Walker, 2007).
It is evident from the above signalling pathways that both ERs have overlapping but
distinct and sometimes antagonistic functions. Tamoxifen exerts differential effect on
target genes depending upon the ER subtype and local context.
1.5.6 Role of ERB in endocrine responsiveness/resistance
Tamoxifen has been the mainstay of hormonal treatment in ERa+ breast cancer for
the past three decades. However, almost all patients with metastatic disease and
approximately 40% of patients who receive adjuvant tamoxifen develop tumour
recurrence and die from breast cancer (Hurvitz & Pietras, 2008; Normannoefal,
2005).
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Loss of expression or mutation of ERa, PgR negative status, cross talk between ER
and growth factor receptor pathways, metabolism of hormonal agents, oestrogen
supersensitivity, oestrogen hypersensitivity and altered expression of coregulators
have all been implicated in hormoneresistance (Normannoef al, 2005). Since its
discovery, the role of ERB in breast hormoneresponsivenesshas also been intensely
investigated. ERa is an accepted but imperfect predictive marker for hormone
responsiveness. The general assumption is that ERB and its isoforms with their
differential expression pattern and function might play a role in hormone
responsiveness. Experimental studies have shown anti-proliferative as well as tumour
suppressive effects for ERB. However, studies investigating the relationship between
ERB expression and hormonaltherapy have produced inconsistentresults.
Miller et al. investigated expression levels of ERa, ERB1 and ERB2 proteins in 36
patients in a neo-adjuvant setting with tamoxifen treatment for three months. All
tumours were positive for ERa and ERB1, whereas ERB2 waspositive in 45% cases
only. 70% of patients showed a clinical response and 48% showed a pathological
response, but there was no significant difference in the expression levels of these
receptors between tumoursthat responded andthat did not. Although ERa expression
was significantly decreased post treatment, no significant difference was seen
between tumours that responded and those that did not (Miller et al, 2006). In
anotherstudy, in the neo-adjuvantsetting, again ERB mRNAlevel wasnotpredictive
of hormone response and there was nosignificant change in expression level post-
treatment (Cappelletti et al, 2004). Speirs et al. measured ERB mRNAin 17 breast
cancer patients treated with tamoxifen and found ERB was upregulated in the
tamoxifen resistant group and the ERB upregulation was also seen in tamoxifen
resistant cell lines (Speirs et al, 1999a). Murphy et al. studied cancer samples in 27
ERa+, node negative patients who received tamoxifen. Total ERB protein as well as
ERB1, ERB2 and ERBS mRNA were measured. High ERB protein expression
correlated with tamoxifen sensitive tumours and no correlation was seen with mRNA
levels (Murphy et al, 2002). Mann et al. performed total ERB immunoanalysis in
118 (ERa+/-) tamoxifen adjuvantly treated patients and showed ERB+ tumours were
significantly associated with increased survival in the whole cohort as well as in the
node negative cohort (Mann ef al, 2001). Hopp et al. measured total ERB by
immunoblot analysis in 186 patients (ERa+/-) treated with tamoxifen and found
25
better survival with high ERB (Hoppet al, 2004). In another study of 52 patients
(ERa+/-) high ERB1 wasassociated with better relapse free survival (Flemingefal,
2004). O’Neill et al. showed ERB1 wasassociated with a trend for worse survival in
138 (ERa-+/-) as well as in 91 ERa+ subgroup. Essilimani-Sahla e¢ al. measured total
ERB and ERP2 protein in 16 tamoxifen-resistant and 34 tamoxifen-sensitive tumours
and found that low levels total ERB, not ERB2 was associated with tamoxifen
resistance (Esslimani-Sahla et al, 2004). Saji et al. assessed ERB2 in 18 breast cancer
in neo adjuvant tamoxifen setting and found poor response to treatment with ERB2
expression (Saji et al, 2002). Palmieri et al. found association between ERf2 protein
and better outcomein a cohort of 23 patients (ERa+) treated with either neo-adjuvant
or palliative endocrine treatment (Palmieri et al, 2004).
The majority of above studies in relation to hormonal treatment showed good
outcome with high ERB. However, somestudies showed nocorrelation or correlation
with poor outcome. Mostof the studies were of small numbers, contained both ERat+
and ERa-patients, unselected patients and used varying methodsto detect the ERB or
its variants. The role of ERB in hormonalresponsivenessisstill unclear.
1.6 Aims and hypothesis
The classical oestrogen receptor (ERa), as a measure of steroid hormone receptor
status, is currently an acceptable prognostic marker that predicts the response to
hormone therapy. However, it is well known that up to 40% of breast tumours with
positive ERa status do not respond to endocrine therapy. Reasons for this lack of
response are poorly understood andthe role of the more recently identified oestrogen
receptor ERB is unclear. In addition to the full-length "wild-type" ERB (termed
ERB1) there are a numberof variants that are expressed in both normal and cancer
tissue and arise from differential splicing (and deletion of exons). A number of
studies have employed RT-PCR,in situ hybridization or immunohistochemistry to
analyse the expression of ERB in mammarytissue and tumours. The results so far are
conflicting, reflecting in part the different case selection or detection techniques
used, and becausethe existence of the variants of ERB can makeit unclear which has
26
been measured. Nevertheless, it has been suggested that the level of ERB expression
may have prognostic or predictive significance in breast cancer.
The aim ofthis study is to further investigate the complex expression of the ERB
variants in breast tumours, in order to establish their relative importance in the
response of patients to endocrine therapy.
Our hypothesis is that particular variants of ERB may be more closely associated
with outcome following adjuvant tamoxifen treatment of breast cancers. Such
variants may be useful as predictive markers.
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Figure 1.1 Age-standardised incidence and mortality from female breast cancerin
Great Britain 1975-2008.
(http://info.cancerresearchuk.org/cancerstats/types/breast/incidence/ 2010, November 27)
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Figure 1.2 Structure of oestrogen receptors.
A. Comparison of ERa, ERB and ERf variants protein structure showing
homology between ERa and ERB1.
B. Alignment of ERB1 protein and mRNAstructure showing protein domains A
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Figure 1.3 The multifaceted mechanisms of oestrogen and oestrogen receptor
signalling (adopted from Speirs & Walker, 2007).
In the classical pathway, oestrogen (E2) binds to ERs to form homodimers or heterodimers
(as shownhere) and recruits co-regulator proteins as part of a complex that binds to EREsin
promoters of target genes, regulating transcription and subsequent tissue responses. In the
non-classical pathway (which is ERE independent), the E2-ER complex can activate
transcription by tethering to alternative response elements such as those for Activator Protein
1 (AP-1) through Jun/Fos-proteins. Growth factors can activate intracellular kinase
pathways, leading to phosphorylation and activation of ER in a ligand independent manner,
attenuating its activity. In the MISS pathway, E2 binds to plasma membrane ER and
activates intra cellular growth factor signalling pathways that generate rapid tissue responses.
Recently, GRP30, a non ERprotein in the plasma membranehasbeenalso thoughtto play a
role in mediating MISS.
ER-Oestrogen Receptor
P-Phosphorylation
ERE-Oestrogen Response Elements
AP-1 —Activator Protein 1
MISS- MembraneInitiated Steroid Signalling
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CHAPTER2 MATERIALS AND METHODS
2.1 Patient selection
Patients undergoing treatment for invasive breast cancer during the period 1993 and
1999 at the Royal Liverpool University Hospital were identified from a database at
the Cancer Tissue Bank Research Centre (CTBRC), University of Liverpool [now
the Liverpool Tissue Bank (LTB), http://www.liv.ac.uk/Itb/].
All patients had provided written, informed consent, at the time of their original
surgery, for their tissue to be donated to the CTBRC for research purposes and also
consented to have their hospital records reviewed in order to provide CTBRC with
clinical follow-up data. Ethical approval for the study was obtained from the
Liverpool Adult Research Ethics Committee (Reference 01/116), who also approved
the collection of samples by the CTBRCwith informed consent (Appendix 1).
A total of 141 patients with primary breast cancer were selected from the CTBRC
database. They were all post-menopausal women and had received adjuvant
hormonal therapy but not systemic chemotherapy. The  clinicopathological
characteristics of the patients included in this study are detailed in Chapter 3 (Table
3.1).
All cases were subjected to full histopathological review, according to the UK
NHSBSPguidelines (National Coordinating Group for Breast Screening, 1997). ERa
and Progesterone Receptor (PgR) status was obtained from review of histopathology
notes where available or were determined immunohistochemically as described later
in this chapter, using a cut-off of 10% positive cells to define the positive and
negative groups.
Initial clinical data for these patients was collected by Dr Penny O’Neill (O'Neill e¢
al, 2004) by retrospective review of patients’ case notes held at the Royal Liverpool
University Hospital NHS Trust. Data comprised of patient demographics including
age at diagnosis, sex, menopausal status, family history and ethnic origin. The
treatment given at diagnosis including details of surgery, radiotherapy and hormonal
therapy werealso collected. Follow-up data for the patients selected was collected by
further retrospective review of patients’ case notes held at the Royal Liverpool
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University Hospital and at Clatterbridge Centre for Oncology by Dr Helen Innes (Dr
H Innes MDthesis, University of Liverpool, 2004). In addition, follow-up data was
requested from patients’ General Practitioners where this was appropriate. Data
recorded included evidence of relapse, including date, site(s), treatment given and
outcome of such treatment. Details of last follow-up or date of death, together with
cause of death and assessment of whether this was related or unrelated to breast
cancer (where this was possible) were also collected. The median follow-up was 71
months for RFS (range 9 to 113) and 79 months for BCS (range 11 to 113).
2.2 Reverse transcription
RNAofsuitable quality for 100 cases was obtained from the CTBRC.Testis, uterus,
prostate and MCF7cell line RNAs were obtained from Clontech Laboratories (USA)
and ovary RNA wasobtained from CTBRC. These were used as controls in the RT
reaction and for the initial cloning of control RT-PCR products used to generate
standard curves.
Cases were selected for RNA analysis following independent histological review of
adjacent sections, so as to avoid high levels of tissue heterogeneity. Samples from all
cases consisted of at least 75% tumour cells and 67% of cases had at least 90%
tumourcells. Inflammatory infiltrates were present in a minority of cases (at 10% in
15 cases and at 25% in 4 cases).
Total RNA (5g) from tumour samples were provided in 201 ethanol. To precipitate
the RNA, 2ul of 3M sodium acetate was added and the sample left at -20°C
overnight. It was then centrifuged at 13000 g at 4°C for 30 minutes andtransferred to
ice. The supernatant was removed and 30ul ethanol used to wash the pellet. The
pellet was dried at 40°C for 10 minutes to evaporate any remaining ethanol. Sul Tris
EDTAbuffer (pH 7.6) was then addedto re-suspendthepellet.
RT reactions were carried out in two steps. Initially single and double strand DNA
present in the tumour sample were digested by Deoxyribonuclease I (DNase I)
(Invitrogen, USA) resulting in purified tumour RNA.In the next step single strand
cDNA was prepared from the tumour RNA by a Reverse Transcriptase enzyme
reaction. This was performed in duplicate, using Superscript HI (Invitrogen), an
a3
RNase H’ Reverse Transcriptase purified to near homogeneity from £.Coli
containing the pol gene of Moloney Murine Leukaemia Virus.
Each 20ul reaction volumeinitially contained: 31 total RNA (1pg/1pl), 21 DNase I
(Invitrogen), 2ul DNase I buffer and DEPC-treated water to 201. This DNAase
digestion reaction was incubated at room temperature for 15 minutes and then
terminated by the addition of 2ul1 EDTA (25mM) and heating to 65°C for 10
minutes. The abovereaction volumewassplit into two 10reactions.
In to the each 101 reaction the following was added: 111 Oligo (dT)j2-13 (Img/ml)
and 1ul 10mM dNTP mix (10mM each dATP, dGTP, dCTP, dTTP at neutral pH).
The reaction was heated to 65°C for 5 minutes followed by a quick chill on ice. The
contents of the tube were collected by brief centrifugation and then added to: 4yl 5X
first strand buffer, 2u] 0.1M DTT, ll Prime Recombinant Ribonuclease Inhibitor
(Eppendorf, Cambridge, UK) and 1pl Superscript III Reverse Transcriptase
(Invitrogen). The final reaction mix was heated to 50°C for 60 minutes and the
reaction terminated by heating to 70°C for 15 minutes. Parallel reactions were
performed in which the RT enzyme was omitted and these acted as controls for
genomic DNAcontamination. RT reactions (cDNAs) werediluted (1/2 dilutions and
1/50 dilutions) and stored to use in quantitative real-time RT-PCR.
2.3 Quantitative real-time RT-PCR
In real-time quantitative PCR (qRT-PCR), the amount of PCR product is measured at
each cycle. This ability to monitor the reaction during its exponential phase enables
users to determine the initial amount of target with great precision. The number of
cycles and the amount of PCR end-product can theoretically be used to calculate the
initial quantity of genetic material (by comparison with a known standard). In real-
time PCR, the amount of DNAis measured after each cycle by the use of fluorescent
markers. The increase in fluorescent signal is directly proportional to the number of
PCR product molecules (amplicons) generated in the exponential phase of the
reaction. Fluorescent reporters used include double-stranded DNA-binding dyes(e.g.
SYBR® Green) or dye molecules attached to PCR probes (e.g. Taqman® probe).
The fluorescence of DNA-binding dyes significantly increases when bound to
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double-stranded DNA (dsDNA). The intensity of the fluorescent signal depends on
the amount of dsDNA that is present. As dsDNA accumulates, the dye generates a
signal that is proportional to the DNA concentration and can be detected usingreal-
time PCR instruments. Taqgman® probes require a pair of PCR primers in addition to
a probe with both a reporter and a quencher dye attached. The probeis designed to
bind to the sequence amplified by the primers. During qPCR,the probe is cleaved by
the 5’-nuclease activity of the Taq DNA polymerase; this releases the reporter dye
and generates a fluorescent signal that increases with each cycle.
Quantitative real-time reverse transcriptase polymerase chain reactions (qRT-PCR)
were performed in a Bio-Rad Icycler PCR Machine (Bio-Rad Laboratories Ltd.,
Hertfordshire, UK). ERf1 (full-length), C-terminal truncations (ERB2/ERBcx, ERB5)
and exon deletions (ERBA5, ERBA3) were quantified with appropriate primers and
Taqman probe (Table 2.1). For ERBAS and ERBA3 PCR, one primer crossed the
deleted exon boundary (Figure 2.1). ERa, GAPDH (Glyceraldehyde-3-phosphate
dehydrogenase) and HPRT (hypoxanthine ribosyltransferase) were quantified with
IQ SYBR Green Supermix (Bio-Rad). GAPDH and HPRT were used to determine
RNAintegrity and RT efficiency and also to validate the quantities of candidate
genes in PCR.
For candidate gene PCR, 4ul of a 1/2 dilution of cDNA was used per reaction
(equivalent to cDNA from approximately 150ng of total RNA). For control gene
PCR (HPRT and GAPDH) and ERa, 4ul of a 1/50 dilution of cDNA was used
(equivalent to cDNA from approximately 6ng of total RNA). Oligonucleotide
primers used for qRT-PCR are shown in Table 2.1 and have been previously
validated (Critchley et al, 2002; Poola, 2003). Reactions included 1x IQ Supermix
(Bio-Rad) and 0.5uM or 1 uM of each PCR primer and 0.2uM of the appropriate
Taqman probe (Table 2.1). The PCR reactions consisted of a hot-start Taq
polymerase activation step of 95°C for 3 minutes, followed by conditions shownto
produce unique, specific bands for each mRNA (Table 2.1 and Figure 2.2). All
ampliconscrossed introns to avoid amplification of genomic DNA (Figure 2.1).
Absolute quantitation of mRNA for each gene was calculated using standard curves
produced with the relevant gene’s cloned cDNA dilutions (Figure 2.3). Briefly,
within the BioRadIcycler software, threshold cycle values are calculated for control
samples(i.e. the point in the PCR reaction at which the amplification curves crosses
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a specific fluorescent value). These are plotted against the log of the starting amounts
(in this case attomole amounts of cloned PCR products), which should give a straight
line. Data at either end of the graph which do notfit on the straight line are removed;
the remaining data are re-plotted and define the dynamic range for the assay (within
which quantitation is reliable). The software calculates an efficiency measure (100%
efficiency being equivalent to a doubling in DNA amount with each cycle) and a
regression equationforthe line. Using this regression equation, starting quantities (in
attomoles) for test samples are calculated from their threshold cycle values. This is
the amount of cDNA that has been put in the PCR reaction; from the proportion of
the Reverse Transcriptase (RT) reaction used in the PCR reaction and the amount(in
ug) of RNA in the RTreaction, this is converted to attomoles per wg RNA.
The mRNAlevels of ERa, ERB1, ERB2, ERB5, ERBAS and ERBA3 are corrected by
a factor calculated by referencing both house-keeping control genes against their
mean values in the cohort. This process was performed for all PCR reactions
including housekeeping control genes. To calculate a correction factor from these
control genes (for differences in cDNA quality arising from RNA quality, RNA
amount andRTefficiency) the quantities of control gene cDNA for each RT reaction
was divided by the mean value of the control gene for the whole cohort. This was
done individually for each control gene (HPRT and GAPDH)and a meancorrection
factor calculated (reducing any abnormal effects of either control gene if used
separately). Dividing each test gene quantity by this correction factor ratio (for each
RTreaction individually as this is where the main variances in cDNA qualityarise)
normalises all quantities to the control genes without changing the units (attomoles
per tg RNA). Replicate corrected absolute quantities for each test gene were then
averaged for each sample. These values were usedin all subsequent analysis.
2.4 Agarose gel electrophoresis
Polymerase chain reaction products were separated and identified by gel
electrophoresis. A 3% agarose gel was prepared by disolving an appropriate quantity
of Seakem agarose (Flowgen) in TAE buffer (40mM Tris acetate, ImM EDTA, pH
7.6) by boiling in a microwave oven. After cooling to 65°C, ethidium bromide
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(0.5ugm/ml) was added for visualisation of the DNA and the gel was poured into a
prepared tray and allowedto cool. Sul of PCR product was mixed with 21 loading
dye [0.25% (w/v) Orange G (sigma), 0.025% (w/v) Xylene Cyanol (sigma) and 40%
(w/v) Sucrose] and 31 of water, and this 101 sample was wet-loaded into the gel
immersed in TAE_ electrophoresis buffer. Molecular weight markers
(PhiX174/HaellI, Abgene) were included on each gel. The gels were run at 120-
150V, scanned on a Typhoon 9400 fluorescent imager (Amersham) and analysed
with ImageQuant version 4.1 software (Molecular Dynamics). This fluorescent
scanner provides an image ofthe gel, with DNA visualised by chelation of ethidium
bromide. Examples of gel electrophoresis are shown in Figure 2.2.
2.5 Cloning and DNAsequenceanalysis
PCR products were cloned into PCR2.1 TOPO plasmid vectors using TOPO TA
cloning® kit (Invitrogen) according to manufacturers guidelines. The cloned cDNA
inserts and flanking vector sequences were then amplified by colony PCR with M13
primers. The PCR reactions were treated with ExoSAP (Amersham Pharmacia
Biotech, to remove unused PCRprimers) and sequenced individually with both M13
primers using DYEnamic ET Dye Terminator Cycle Sequencing Kit for MegaBACE
(Amersham Pharmacia Biotech). Sequencing products were purified (AutoSeq plate,
Amersham Pharmacia Biotech) and analysed on a MegaBACE 1000 DNAanalyser
(Molecular Dynamics). The identities of the cloned cDNAs were confirmed by
performing web-based database searching via BLAST at the NCBI
(www.ncbi.nlm.nih.gov). Example DNA sequence and BLASTalignments are given
for ERBAS (Figure 2.4) and ERBA3 (Figure 2.5).
2.6 Immunohistochemistry (IHC)
Histological sections (4um) were cut from archival formalin-fixed, paraffin-
embedded specimens and provided by CTBRC on 2% 3-aminopropyltriethoxysilane
(APES) coated slides. All sections were cut from formalin-fixed, paraffin-embedded
archival specimens in September 2001 and stored in room temperature until
September 2005, whenthis experiment was performed.
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Mouse anti-human ERB2 monoclonal antibody MCA2279S(clone no 57/3; Serotec
Ltd, Oxford, UK) was employed to recognise the ERB2 isoform. Optimisation of the
immunohistochemistry wasinitially performed by antibody kindly donated by Dr P
Saunders (Edinburgh) and further validated with MCA2279S purchased from
Serotec. Specificity of the antibody was confirmed by incubation with pre-immune
serum. For detection of ERa, a mouse anti-human ERa monoclonal antibody was
used (Clone 1D5, Dakocytomation Ltd, Ely, Cambridge, UK). Progesterone receptor
(PgR) status was measured using a mouse monoclonal anti-PgR antibody (Clone
636, Dakocytomation Ltd, Ely, Cambridge, UK).
ERf2 immunostaining
Formalin-fixed and paraffin wax-embedded sections of normal and malignant breast
tissues were used for immunostaining. After de-waxing and rehydration, the slides
were immersed in 3% hydrogen peroxide (30ml 30% hydrogen peroxide in 270mlof
alcohol) for 15 minutes to block the endogenous peroxidases. Antigen retrieval was
by microwavingthe slides for 10 minutes in Antigen Unmasking Solution (H3300,
Vector Laboratories Ltd., Peterborough, UK). Then slides were incubated in Protein
Block Serum-Free (DakoCytomation, California, USA) for 10 minutes. Slides were
incubated overnight at 4°C (Saunders et al, 2002) with ERB2 antibody diluted (1:25)
in 0.1% (w/v) BSA in phosphate buffered saline. Antibody binding was detected by
applying biotinylated link antibody solution, followed by the streptavidin-HRP
solution (LSABP2® System-HRP, DakoCytomation, California, USA), both for 30
minutes at room temperature. Slides were then incubated in 3,3’-diaminobenzidine
(Sigma, St Louis, USA) for five minutes before counterstaining in Harris
Haemotoxylin (Sigma, St Louis, USA) for 1.5 minutes. Slides were agitated in acid
alcohol [1% (v/v) HCL in 70% (v/v) alcohol] for 15 seconds and then quickly dipped
in Scott’s tap water substitute for 15 seconds. Sections were dehydrated and mounted
with DPX (Fisher Scientific UK Ltd, Loughborough, UK). Positive (control tissue)
and negative (no primary antibody) controls were included in each batch ofstaining.
In somenegative controls the ERB2 antibody waspre-incubated with a molar excess
of immunising synthetic peptide CMKMETLLPEATMEQ (MCA928,clone W3/25,
Serotec Ltd, Oxford, UK) (Saji et al, 2002; Saunders et al, 2002) prior to application
to sections from specimens previously shown to stain positively. Nuclear staining
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was abolished in these blocked controls, but some cytoplasmic staining remained.
Scoring of tumoursections was performed for nuclear staining only.
ERaand PgR immunostaining
The immunostaining technique was similar to the above except the following steps.
Slides were not incubated in Protein Block Serum-Free (DakoCytomation,
California, USA) after antigen retrieval step. The ERo antibody (1:30 dilution) and
PgR antibody (1:50 dilution) were applied to slides and incubated for 40 minutes at
room temperature.
Assessment of immunostaining
Analysis wasrestricted to the epithelial componentofall tissues. Stained slides were
analysed independently by two observers (myself and Dr Vijay Aachi, Consultant
Breast Pathologist, Royal Liverpool and Broadgreen University Hospital) using light
microscopy. The percentage of positively stained malignant cells was estimated as
was the staining intensity (weak, moderate and strong), and an immuno-score
calculated according to the Allred system as shown in Table 2.2 (Harveyet al, 1999).
The Allred scoring system is the currently validated and accepted scoring system
across the UK and manyother countries for ERa and PgR.
2.7 Statistical methods
Power calculations were performed using the PS program (Dupont & Plummer,
1998) with survival analysis implementation of Schoenfeld and Richter (Schoenfeld
& Richter, 1982). Based on estimates of proportions of ERB2 positive cases from the
previous study from our laboratory (Davies et al, 2004) and available outcome data,
we determined that this study would have 80% power with an a value of 0.05 to
detect a hazard ratio below 0.73 or above 1.40 in the whole cohort (below 0.63 or
above 1.74 in the ERa + cohort), which we considered appropriate to give an
indication ofclinicalutility.
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All other statistical analyses were performed using the SPSS® package (Windows,
v.13). The degree of agreement between observers was assessed using the Kappa
statistic; a value of >0.61 was taken to be a satisfactory agreement (Altman, 1991).
Pearson correlation and Spearman’s rank correlation were used as a measure of
association between abundance of mRNA and the degree of immunohistochemical
staining. The Student’s t-test and the Mann-Whitney U test (MW) were used to
compare the levels of mRNA orprotein between cases defined by other parameters.
For paired data, paired T-tests and Wilcoxonsigned ranks tests were used.
Relapse Free Survival (RFS) was defined as any recurrence or metastasis to local,
contralateral, regional, and distant locations. Breast Cancer Survival (BCS) was
calculated from any breast cancer related mortality. Optimal cut-points (e.g. for the
continuous variables given by qRT-PCR analysis) were determined using Receiver
Operating Characteristic (ROC) plots for relapse free survival (RFS) and breast
cancer survival (BCS) at 5 years after surgery. Individualized ROC plots were
determined for various subgroup analyses. Curves for outcome were generated using
the Kaplan-Meier method for censored data, with surviving patients’ data being
censoredat the date of their last clinic visit. Curves from different groups of patients
were compared using the log rank test. Unadjusted hazard ratios (HR) + 95%
confidence intervals (CI) were obtained using Cox’s univariate analysis. Cox’s
regression model was used for multivariate survival analysis (Altman, 1991) and
stratified Kaplan Meier plots with log rank tests were used to further investigate the
interaction between two outcomerelated variables.
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Table 2.2 Allred scoring system used for scoring immunohistochemistry.
 Percentage score for proportion Scorefor staining intensity
 of staining
0 = No nuclearstaining 0 = Nostaining
1 =<1% nuclei staining 1 = Weakstaining
2 = 1-10% nucleistaining 2 = Moderate staining
3 = 11-33% nuclei staining 3 = Strong staining
4 = 34-66% nuclei staining
5 = 67-100% nuclei staining
 
Allred score = Percentage staining score + Intensity score
 DN
A-
bi
nd
in
g
do
ma
in
?
Li
ga
nd
-b
in
di
ng
do
ma
in
e
e
t
 
AIB
 
¢
D re
a
 
ex
on
1
2
3
4
 
 
5
6
7
8
—>
—_
—~
<- 
 
 
 
 
<a
|
>
|
AP
T?
B=]
Ee
+
—
AF2
—
s
 [6
12
6
F |
B
1
5
R
in
all
ern
ati
ve
ex
on
Bs
 
  
Fi
gu
re
2.1
ER
st
ru
ct
ur
e w
ith
loc
ati
on
of
pri
mer
s f
or
the
ER
B v
ari
ant
spe
cif
ic
(R
T-
PC
R.
Pr
im
er
s w
er
e d
esi
gne
d
in
suc
h a
wa
y t
o m
axi
mis
et
he
spe
cif
ici
ty.
F-
Fo
rw
ar
d p
rim
er;
R-
Re
ve
rs
e p
rim
er.
Fo
r d
ele
tio
n v
ari
ant
s,
at
lea
st
on
e p
rim
er
cro
sse
d t
he
ex
on
bou
nda
ry.
Fo
r C
-te
rmi
nal
var
ian
ts
ER
B1
an
d E
RP
S t
he
sa
me
for
war
d p
rim
ers
wer
eu
se
d,
but
dif
fer
ent
spe
cif
ic
rev
ers
e p
rim
ers
. F
or
ERB
2,
se
pa
ra
te
fo
rw
ar
d a
nd
rev
ers
e p
rim
ers
we
re
use
d.
42
43
5
- aSS OR en Ae RE HU Me Rt Ae et eh KE ER el) mh tema ese ="<— 163 bp GAPDH
1,353
1,078
oN ;a281ef eeeeeeOe Seeeeeeeeeee eeeeeeeeOE 167 DO HPRT
264 /=
ae
118
72 =
ee eeeeee ene ome 4— 128 bp ERa
He ale = ie at a eS “—e
=
” ak Ue Gm te tee ow eee tee in Sed ee ce tei ee — =e “= *<+ 186 bo ERB1
d = ss
? ‘
a c i 2 i aw me 2S lee Sa Ok ee ae Gee ee eae oldie » » 478 bp ERB2
F can ee Se SO SP HE St SOGE eePEONtS OP = ¢— 177 bp ERB5S
=
SS ee ee ee ee oS 2S OF OF = SS ‘ aver + 241 bp ERBAS
fi
l
i
aa
d
« _ = 283 bp ERBA3
Figure 2.2 Examples of agarosegel electrophoresis forRT-PCR products. Onthe
left hand side of the gel, standard sizes of the molecular weight markers are shown
and on the right hand side the PCR products identity and their expectedsizes are
shown.
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Figure 2.3 Real time PCR quantitation (A) and standard curve (B).
In A, Relative Fluorescent Units (RFU) for baseline subtracted data are plotted against cycle
number. Rainbow coloured curves with squares were from serially diluted cloned PCR
standards (blue coloured circles in plot B). Various coloured lines without square markers
represent unknown breast cancer samples (red squares in standard curve in plot B). The
orange horizontalline in A is the threshold at which Ct values are calculated.
In B, Ct values for standards were plotted against log of knownstarting quantities to provide
a linear plot from which unknown tumour sample values can be extrapolated.
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A. ERBAS DNA sequenceanalysis
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Vector(exon 4/6)   
B. ERBAS5S BLASTresult
oT|ret in ee21 Ey) Homo sapiens estrogen receptor 2 (ER beta} (ESR2}, transcript
variant a,
e
GENE ID: 2100 ESR2 | estrogen receptor 2 (ER beta) [Homo sapiens]
{Over 100 PubMed links)
8e-1106
1/228 (0%)Score = 403 bits (446), ExpectIdentities = 227/228 (99%), Gaps
Strand=Plus/Plus
Query 97 CGGCAAGGCCAAGAGA-GTGGCGGCCACGCGCCCCGAGTGCGGGAGCTGCTGCTGGACGC «155PUPPET EEE EEE PEPE PEEP EEE EEE EEE EEE EEEeed
Sbjct 1194 CGGCAAGGCCAAGAGAAGTGGCGGCCACGCGCCCCGAGTGCGGGAGCIGCIGCIGGACGC 1253
Query 156 CCTGAGCCCCGAGCAGCTAGTGCTCACCCTCCTGGAGGCIGAGCCGCCCCATGTGCTIGAT 215POEEEEEEEEEEEE EEE EEE EEE E EEE EEE PEPE EEE Eee ere
Sbjct 1254 CCTGAGCCCCGAGCAGCTAGTGCTCACCCTCCTGGAGGCIGAGCCGCCCCATGIGCIGAT 1313
Query 216 CAGCCGCCCCAGTGCGCCCTTCACCGAGGCCTCCATGATGATGTCCCTGACCAAGTIGGC 275PODEEEEEEEEEEE DEEPER EEE EEE EEE EEEeee
Sbjct 1314 CAGCCGCCCCAGTGCGCCCTTCACCGAGGCCTCCATGATGATGICCCIGACCAAGTTGGC 1373
Query 276 CGACAAGGAGTTGGTACACATGATCAGCTGGGCCAAGAAGATICCCGG 323
PEEP EEE EE ERED EESbjct 1374 CGACAAGGAGTTGGTACACATGATCAGCTGGGCCAAGAAGATTCCCGG 1421
Figure 2.4 ERBAS sequenceanalysis (A) and BLASTresult (B) confirmingthe
identity of PCR product; alignment matchindicated by white backgroundin A.
46
A. ERBA3 DNA sequenceanalysis
 
Vector Forward Primer (exon 2/4)
L VSAAVFOUG AG AGA AGG G
fd Pee AY vy
TTAA A AA
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Li kt
 
 
         CCCEG
  
Reverse Primer Vector   
B. ERBA3 BLASTresult
oT|ret in 001437.21 Eo Homo sapiens estrogen receptor 2 (ER beta) (ESR2), transcript
MRNAvariant a,
Length=2169
GENE ID: 2100 ESR2 | estrogen receptor 2 (ER beta) [Homo sapiens]
(Over 100 PubMed links)
Score = 480 bits (532), Expect = 4e-133
Identities = 266/266 (100%), Gaps = 0/266 (0%)
Strand=Plus/Plus
Query 90 GGCTCCCGGAGAGAGAGATGTGGGTACCGCCTIGTGCGGAGACAGAGAAGTGCCGACGAG 4143PEPE UPPEREEEEeeSbjct 1120 GGCTCCCGGAGAGAGAGATGTGGGTACCGCCTIGTGCGGAGACAGAGAAGTGCCGACGAG 1179
Query 150 CAGCTGCACTGTGCCGGCAAGGCCAAGAGAAGTGGCGGCCACGCGCCCCGAGTGCGGGAG 9209
PEP EEP CUP E EPC ET EEE EEeee
Sbjct 1180 CAGCTGCACTGTGCCGGCAAGGCCAAGAGAAGTGGCGGCCACGCGCCCCGAGTGCGGGAG 1239
Query 210 CTGCTGCTGGACGCCCTGAGCCCCGAGCAGCTAGTGCTCACCCTCCIGGAGGCIGAGCCG 269
PEEPS E EET E EET E EEE EEE EEEEEE
Sbjct 1240 CTGCTGCTGGACGCCCTGAGCCCCGAGCAGCTAGTGCTCACCCTCCIGGAGGCTGAGCCGE 129%
Query 270 CCCCATGTGCTGATCAGCCGCCCCAGTGCGCCCTTICACCGAGGCCTICCATGATGATGTCC 329
PEPEU EP ED ED EPEC EEE EEE ee
Sbjct 1300 CCCCATGTGCTGATCAGCCGCCCCAGTGCGCCCTICACCGAGGCCTCCATGATGATGICC 1359
Query 330 CTGACCAAGTTGGCCGACAAGGAGTT 355
PLTEEETEPP
Sbjct 1360 CTGACCAAGTTGGCCGACAAGGAGTT 1385
Figure 2.5 ERBA3 sequenceanalysis (A) and BLASTresult (B) confirming the
identity ofPCR product; alignment match indicated by white backgroundin A.
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CHAPTER3 RESULTS 1
CLINICOPATHOLOGICAL DATA
3.1. Introduction
Patient selection is a very important process when evaluating biomarkers in a
treatment specific population. There is a need to avoid factors that might unduly
influence apparent expression of the biomarkers and to carefully select patients who
received uniform treatment. Nevertheless, it is also useful if the cohort is
representative of the general population. Every effort should be made to avoid
selection bias and the cohort should have enough numbers to provide valid results.
Therefore, having selected the cohort, here we analyse standard clinical markers in
order to verify that they behaved as one might expect. This validates the cohort for
further investigation of novel markers.
The Patient’s clinical and pathological characteristics were obtained from Candis
Cancer Tissue Bank Research Centre (CTBRC), University of Liverpool, Liverpool.
Patient’s treatment and follow-up data, which were collected retrospectively and
stored in CTBRC were available for outcome analysis. All the patients who
underwent operations for primary breast cancer between 1993 and 1999, and kindly
donated tissue for research wereinitially analysed. From this large patient group, a
specific cohort of patients who were postmenopausal womenandreceived adjuvant
endocrine therapy but not chemotherapy was then selected; patient had either
mastectomy or wide local excision with or without axillary lymph node surgery and
radiotherapy. Patients who had neo-adjuvant therapy were also excluded from the
study. This gave us 141 cases for the study. Paraffin tissue sections for
immunohistochemistry (IHC) were available for all the cases and suitable quantity of
tumour RNA for qRT-PCR wasavailable for 100 cases.
3.2 Summaryof patient characteristics — IHC cohort
All the patients (Table 3.1) were postmenopausal women (n=141) and median age
was 68 years (range 47 to 87). Postmenopausal status was obtained from patients
notes. Staging investigations to exclude metastatic disease varied but generally
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included chest radiograph andliver function tests and none ofthe patients had distant
metastasis at the time of diagnosis.
They had been treated by surgery (47 mastectomy, 94 wide local excision). The
overwhelming majority of cancers were less than 5cm in size (63 cancers were less
than 2 cm in size and 74 were 2-5 cm in size) and in the remaining 4 cases, 3 cases
were more than 5 cm in size (5.5, 6.5 & 8 cm) and it was not available for 1 case.
Someform of axillary staging was carried out in118 patients. 51 cases had positive
nodes in the axilla. Further analysis of nodal status showed that 36 cases were
positive for 1-3 nodes, 10 cases were positive for 4-9 nodes and the remaining 5
cases had more than 10 positive nodes.
70 cases had adjuvant radiotherapy either to breast (n=40), breast and axilla (n=25)
or breast and supra clavicular fossa (n=2) or chest wall (n=1) and, chest wall and
supra clavicular fossa (n=2). All patients did receive adjuvant endocrine therapy;
either tamoxifen (n= 133) or as part of the ATACtrial (n=8, blind to regimen at the
time of study), but no one received systemic chemotherapy or primary endocrine
therapy.
The majority of the cancers were invasive ductal carcinoma (n=121) and 11 cases
were invasive lobular carcinoma and the remaining were rare type of tumours
(Table3.2). The majority of the tumours were grade 3 (n=61) followed by grade 2
(n=58), and the remaining were grade 1 (n=22). Vascular invasion waspresent in 60
cases and was absentin 81 cases.
ERa status was obtained from CTBRC where available (n=136) and for the
remaining cases (n=5) ERa staining was done as part of the current study using
standard protocol. Progesterone receptor (PgR) status was obtained from CTBRC for
121 cases andfor the rest of the cases (n=20), PgR staining wascarried out aspart of
the current study. For ERa and PgRstatus a cut-off of 10% positive cells was used to
define the positive and negative groups (O'Neill et al, 2004). In this cohort, 98 cases
were positive and 43 were negative for ERa and, 69 cases were positive for PgR and
72 were negative for PgR. All patients received adjuvant endocrine therapy
irrespective of ERa status (ERa status was not routinely measured for breast cancer
patients before 1996).
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3.3 Association between clinicopathological characteristics — THC
cohort
ERa-+ status was associated with low-grade tumours (Chi-square P<0.001) (Figure
3.1), invasive ductal carcinoma (Chi-square P=0.032) and PgR positivity (Chi-square
P<0.001), but not related to tumour size, nodal status and vascular invasion. PgR
positivity was associated with low-grade tumours (Chi-square P<0.001), invasive
ductal carcinoma (Chi-square P=0.030) and negative nodal status (Chi-square
P=0.024). Positive nodal status was associated with large tumour size (Chi-square
P=0.021, T-test P=0.0047) (Figure 3.2), high-grade tumours (Chi-square P=0.020),
and lymphovascular invasion (Chi-square P<0.001). Invasive ductal carcinoma was
associated with high-grade tumours (Chi-square P=0.006) and lymphovascular
invasion (Chi-square P=0.001).
3.4 Survival analysis for clinicopathological characteristics — IHC
cohort
Survival analysis [Relapse free survival (RFS) and Overall survival (BCS)] was
performed for the established markers using Kaplan Meier method. Survival Curves
for outcome were generated using the Kaplan-Meier method for censored data, with
surviving patients’ data being censored at the date of their last clinic visit; curves
from different groups of patients were compared using the log rank test.
In Kaplan-Meier survival analysis, ERa+ status, PgR positivity, low grade (grade 1
vs. 2 vs. 3 and grade 1&2 vs. 3), negative nodal status, small primary tumour and
cancers other than IDC wereassociated with good outcome (Table 3.3). Vascular
invasion was not associated with outcome. Kaplan Meier survival plots for ERa
status, tumour grade, nodal status and PgR status were shown in Figure 3.3 for RFS
and Figure 3.4 for BCS.
Cox univariate analysis showed that ERa positive status, PgR positive status, low
grade of the tumour (1&2 vs. 3), negative nodal status and cancers other than
invasive ductal carcinoma (IDC vs. other types) were associated with better relapse
free (RFS) and overall survival (BCS). Small tumours were associated with better
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overall survival and also showed a trend towards better relapse free survival (Table
3.3). Lymphovascular invasion wasnot associated with survival.
Cox multivariate analysis was carried out including ERa status, PgR status, grade of
the tumours (1&2 vs. 3), nodal status, tumour size (less than 2cm vs. more than 2cm)
and tumourhistology (IDC vs. Other types). For RFS, only negative nodal status (HR
3.08 CI 1.56 to 6.06; P=0.001) and low grade (HR 1.54 CI 1.10 to 2.16; P=0.012)
were associated with good outcome. There was a trend for better RFS for PgR
positive status (HR 1.54 CI 0.28 to 1.09; P=0.086).
For BCS,negative nodal status (HR 2.85 CI 1.33 to 6.11; P=0.007) and PgRpositive
status (HR 0.40 CI 0.18 to 0.91; P=0.029) were associated with good outcome. There
wasa trend for better BCS for low tumourgrade (HR 1.42 CI 0.97 to 2.08; P=0.069).
In the ERa+ tamoxifen treated cohort (n=91), PgR positivity, low grade-(gradel vs.
2vs. 3 and gradel&2 vs. 3), negative nodal status and small primary tumour were
associated with good outcomein Kaplan-Meier survival analysis and Cox univariate
analysis (Table 3.3). In multivariate analysis for RFS only negative nodal status (HR
3.91 CI 1.48 to 10.3; P=0.006) was associated with good outcome. There wasa trend
for better RFS for low grade (HR 1.52 CI 0.97 to 2.39; P=0.070). For BCS,similarto
the whole cohort, negative nodal status (HR 4.39 CI 1.53 to 12.56; P=0.006) and
PgR positive status (HR 0.33 CI 0.12 to 0.91; P=0.033) were associated with good
outcome.
3.5 Summaryofpatient characteristics — qRT-PCR cohort
All the patients were postmenopausal women (n=100) and median age was 68 years
(range 48 to 87). They had been treated by surgery (33 mastectomy, 67 wide local
excision) and 44 cancers were less than 2 cm in size and 53 were 2-5 cm in size and
in the remaining 3 cases, 2 cases were more than 5 cm in size (5.5 & 8 cm) andit
was not available for 1 case. Some form of axillary staging was carried out in 88
patients. 39 cases had positive nodes in the axilla. Further analysis of nodal status
showedthat 31 cases were positive for 1-3 nodes, 5 cases were positive for 4-9 nodes
and the remaining 3 cases had more than 10 positive nodes.
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49 cases had adjuvant radiotherapy either to breast (n=28), breast and axilla (n=17)
or breast and supra clavicular fossa (n=2) or chest wall (n=1) and, chest wall and
supra clavicular fossa (n=1). All patients did receive adjuvant endocrine therapy;
either tamoxifen (n= 93) or as part of the ATACtrial (n=7, blind to regimen during
study period), but no one received systemic chemotherapy or primary endocrine
therapy.
The majority of the cancers were invasive ductal carcinoma (n=85) and 8 cases were
invasive lobular carcinoma and the remaining were rare type of tumours. The
majority of the tumours were grade 3 (n=42) and grade 2 (n=44), and the remaining
were grade 1 (n=14). Vascular invasion was present in 41 cases and wasabsent in 59
cases (Table 3.1).
ERa and PgRstatus were obtained from CTBRCfor the majority of the cases, but as
described previously additional staining was performed where status was unknown,
70 cases were positive and 30 were negative for ERa. In this cohort, 53 cases were
positive and 47 were negative for PgR.
3.6 Association between clinicopathological characteristics — qRT-
PCRcohort
Most of the correlations between clinicopathological characteristics seen in [IHC
cohort were maintained in the 100 patient cohort, but there were somedifferences.
ERa+ status was associated with low-grade tumours (Chi-square P<0.001) and PgR
positivity (Chi-square P<0.001), but not related to tumoursize, nodal status, tumour
histology and lymphovascular invasion. Positive nodal status was associated with
PgRpositivity (Chi-square P=0.021), lymphovascular invasion (Chi-square P=0.001)
and high-grade tumours (Chi-square P=0.045), but was no longer associated with
tumour size (Chi-square P=0.109) or grade (Chi-square P=0.126) in this 100 patient
cohort. Invasive ductal carcinoma type wasassociated with lymphovascular invasion
(Chi-square P=0.003) and high-grade tumours (Chi-square P=0.014).
Lymphovascular invasion was also associated with higher TNM stage (Chi-square
P=0.017).
a2
3.7 Survival analysis for clinicopathological characteristics — qRT-
PCR cohort
Survival analysis was performed for this cohort similar to the immuno cohort using
Kaplan Meier method. In Kaplan Meier survival analysis, ERat+ status, PgR
positivity, low grade (gradel vs. 2vs. 3 OR gradel&2 vs. 3), negative nodal status,
small primary tumour and cancers other than IDC were associated with good
outcome (Table 3.4). Vascular invasion was not associated with outcome.
Cox univariate analysis showed that ERa positive status, PgR positive status, low
grade of the tumour (1&2vs. 3), negative nodal status and invasive ductal carcinoma
(IDC vs. Other types) were associated better relapse free (RFS) and overall survival
(BCS). Small tumours were associated with better overall survival, but not with
relapse free survival (Table 3.4). Lymphovascular invasion did not show correlation
with survival.
Cox multivariate analysis was carried out including ERa status, PgR status, grade of
the tumours (1-2 vs. 3), nodal status and tumoursize (less than 2cm Vs more than
2cm) tumour histology (IDC vs. other types). For RFS, negative nodal status (HR
3.05 CI 1.36 to 6.84; P=0.007) and low tumour grade (HR 1.55 CI 1.05 to 2.27;
P=0.026) were associated with good outcome. For BCS, once again negative nodal
status (HR 3.46 CI 1.33 to 8.99; P=0.001) and low tumour grade (HR 1.75 CI 1.11 to
2.77; P=0.017) were associated with good outcome.
In the ERa+ tamoxifen treated cohort (n=64), low grade (gradel vs. 2 vs. 3 and
gradel&2 vs. 3) and negative nodal status were associated with good outcome in
Kaplan-Meier survival analysis and Cox univariate analysis. There was a trend for
PgR positivity for BCS (Table 3.4). In multivariate analysis, for RFS, only negative
nodal status (HR 3.14 CI 1.09 to 9.01; P=0.03) was associated with good outcome;
for BCS, only grade (HR 3.08 CI 1.21 to 7.81; P=0.018) was associated with good
outcome.
a0
3.8 Discussion
Whenundertaking a study of predictive markers, or a survey of expression in relation
to clinicopathological features, it is important to assess the extent to which the cohort
reflects the wider population,or the clinically relevant treatment group.
Patients selected in this study were from the CTBRC (Cancer Tissue Bank Research
Centre) database from a single institute. The patient selection was done with the aim
of the study in mind, to assess the role of ERB in adjuvant endocrine treated
postmenopausal primary breast cancer. Comparison of this database and the cohort
of patients selected for this study were made with the Surveillance, Epidemiology,
and End Results (SEER) data of the National Cancer Institute (Carter et al, 1989)
(Table 3.5). The majority of breast cancers were invasive ductal carcinoma followed
by lobular carcinoma and there were more node-negative cancers than node-positive
cancers in both studies. The majority of tumours were 2-5 cm in size in both studies
(55% vs. 53 %); however, tumours measuring less than 2 cm were significantly
higher in this study (45% vs. 34%). This is despite a somewhat lower proportion of
smaller tumours (30%) in the CTBRC as a whole, presumably as there was a
tendency to bank predominantly large tumours. Hence this cohort may not be fully
representative of a random sample of breast cancers. However, the patients included
in the study were highly selective, as they are all postmenopausal women and
received adjuvant endocrine therapy and no neo-adjuvant therapy. Possible reasons
for this discordance with unselected series include that this cohort being
postmenopausal,is likely to contain more screen detected tumours whichare usually
smaller; and being selected for adjuvant endocrine therapy only, is likely to contain
fewer large tumours that required chemotherapy.
Significant benefits of careful patient selection include more consistent assessment of
hormonal factors and a better measure of treatment specific outcomes. Measurement
of oestrogen receptor expression in postmenopausal women is more consistent as
expression may vary with menstrual status in premenopausal women. Patients who
received neo-adjuvant chemotherapy or endocrine therapy were excluded, so that any
effect on ERB levels from previous treatment was avoided. Patients receiving
adjuvant chemotherapy were excluded, to focus on the endocrine treatment effect
alone.
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This retrospective cohort included 43 patients who received endocrine therapy, but
later found to be ERa negative. Inclusion of such patients allowed the investigation
of relationships between ERand clinicopathological characteristics in primary
tumoursin relation to both ERa. positive and negative status. Whilst this allows one
to address the biology of breast cancer, relation to outcome is best studied in the
morerestricted ERa positive subgroup receiving endocrine treatment.
In this study, the majority of the tumours were invasive ductal carcinoma, andthis
histological type was associated with worse outcome compared to other types. Ellis
et al. analysed a series of 1621 women, who underwent primary breast cancer
operation, but did not receive any adjuvant systemic treatment. Invasive lobular
carcinoma and special types like tubular, invasive cribriform and mucinous
carcinoma were associated with better prognosis than invasive ductal carcinoma of
no special type (Ellis et al, 1992). Hence the prognostic impact of invasive ductal
carcinomais apparently maintained in this postmenopausal endocrine treated cohort.
ERa positive patients had better survival compared to ERa negative patients, as
expected from the prognostic and predictive value of ERa. Association between ERa
positive status and better relapse free survival wasfirst noted in 1977 (Knightet al,
1977). Further studies showed that ER positivity was associated with both relapse
free as well as overall survival (Hawkinset al, 1987; Parl et al, 1984). Barneset al.
showedin a study of 831 patients (659 ERa+ and 172 ERa-) treated with adjuvant
tamoxifen, with 6.5 years of median follow-up, ERa+ patients had better survival
(Barnes et al, 2004). Association between ERa status and outcome in the present
study were entirely consistent with these previous findings and the knownbiology of
tamoxifen action.
Low grade tumours were associated with better relapse free and overall survival.
Again this was well recognised in previous studies (Elston & Ellis, 1991; Fisher er
al, 1993). Positive nodal status was associated with high-grade tumours, large
tumours and lymphovascular invasion. Many studies have shown a direct
relationship between tumoursize and the probability of lymph nodal involvement
(Carter et al, 1989; Nemoto ef al, 1980). Positive nodal status and large tumour were
associated with poor prognosis, as seen in previous studies (Carter et al, 1989;
Donegan, 1992; Gebaueref al, 2002).
aD
Therefore, even though the study was highly selective and relatively small, the
association between the clinicopathological characters were similar to most of the
published literature from unselected patient cohorts. In spite of the relatively small
number of cases studied, the outcome analysis of the standard markers (e.g. nodal
status, grade, size and ERa) was again consistent with previous larger studies. Hence
this cohort provides a good basis to further explore novel associations between
outcome and alternative markers, such as those provided by ERf andits splice
variants.
Table 3.1 Patient characteristics
 
Characteristics Immunohistochemistry qRT-PCR
Cohort n=141 (“%) Cohort n=100
 
 
 
Surgery Mastectomy 47 (33.3) 33
WLE 94 (66.7) 67
Radiotherapy Yes 70 (49.6) 49
No 71 (51.4) 51
Histology Invasive ductal 121 (85.8) 85
Others 20 (14.2) 15
Grade Gl 22 (15.6) 14
G2 58 (41.1) 44
G3 61 (43.3) 42
Size Tl 63 (44.7) 44
T2 74 (52.5) 53
T3 3 (2.1) 2
Unknown 1 (0.7) l
Nodalstatus + 51 (36.2) 39
- 67 (47.5) 49
Unknown 23 (16.3) 12
Vascular invasion Present 60 (42.6) 4]
Absent 81 (57.4) 59
ERoa - 98 (69.5) 70
- 43 (30.5) 30
PgR + 69 (47.5) 53
: 72 (52.5) 47
Table 3.2 Histological types
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Histological Type
 
No of cases-whole
cohort n=141 (%)  
No of cases-qgRT-PCR
cohort (n=100)
Invasive ductal carcinoma
Invasive lobular carcinoma
Mucinous carcinoma
Papillary
Tubular
Medullary
Mixed mucinousand papillary
121 (85.8)
11 (7.8)
5 (3.5)
1 (0.7)
1 (0.7)
1 (0.7)
1 (0.7)
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Table 3.5 Comparison of CTBRC cases with SEER data.
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SEER CTBRC THC qRT-PCR
data data cohort cohort
Numberofcases 24 740 379 141 100
Histological Ductal (NST) 83.4% 88.2% 85.8% 85%
type Lobular 7.4% 6.3% 7.8% 8%
Others 9.3% 5.5% 6.4% 7%
Size <2cm 33.6% 29.5% 45.0% 44.0%
2-Scm 55.4% 63.0% 52.9% 53.0%
>S5cem 10.9% 7.5% 2.8% 2.0%
Nodal Status Negative 54.4% 46.0% 56.8% 55.7%
Positive 45.5% 54.0% 43.2% 44.3%
 
CTBRC:Cancer Tissue Bank Research Centre
SEER: Surveillance, Epidemiology, and End Results (SEER) data of the National
CancerInstitute
NST: No Specific Type
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Figure 3.1 Association between ERapositivity and low grade tumours.
ERa+ status was associated with low-grade tumours.
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Figure 3.2 Association between positive nodalstatus and large tumours.
Positive nodal status was associated with large tumoursize.
The box represents the interquartile range, the line across the box indicates the median. The
whiskers extend from the box to the highest and lowest values [excluding outliers (+) and
extremes(X)]
Cu
mu
la
ti
ve
Su
rv
iv
al
Cu
mu
la
ti
ve
Su
rv
iv
al
62
 
       
 
       
A. ERa B. Grade
1.04 1.04
n=77
0.85 g 0.854 Grade1&2
20.6 H 06
®2
0.44 B 044SsE
0.2 Neg. O 024
Log Rank P<0.001 Log Rank P<0.001
0.07 0.05T T T T T T T T T T ! T
0 20 40 60 80 100 120 0 20 40 60 80 100 120
Follow-up (months) Follow-up (months)
C. Nodal status D.PgRstatus
1.075 1.04
0.84 S os
E0.64 A 06-
o20.44 044
s& Neg.
0.2 3S 024Log Rank P<0.001 2 Log Rank P<0.001
0.05 0.0-
i T ! T T T T T0 a 2 so @ OD 0 0 20 40 «2.60 80 100 120
Follow-up (months) Follow-up (months)
Figure 3.3 Kaplan Meiersurvival plots for relapse free survival (RFS) for standard
markers in IHC cohort. ERa+ status, PgR+ status, lower tumour grade and negative
nodal status were associated with better RFS.
Crosses on the lines represent censored data.
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Figure 3.4 Kaplan Meier survival plots for breast cancer survival (BCS) for
standard markers in IHC cohort. ERa+ status, PgR+ status, lower tumour grade and
negative nodal status were associated with better BCS.
Crosses on the lines represent censored data.
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CHAPTER 4 RESULTS2
mRNA QUANTITATION AND ANALYSIS FOR ERa,
ERB1, ERB2, ERB5, ERBAS AND ERBA3
4.1 Introduction
The hypothesis being tested relies on measurement of individual splice variants of
ERB. This can be achieved using validated, variant specific, quantitative RT-PCR
assays. Relationship to clinicopathological parameters and outcomes can then be
tested using appropriate statistical methods.
Oestrogen receptors were measured at the mRNAlevel, fully quantitatively, in 100
cases where suitable quantity of tumour RNA wasavailable, in samples where the
proportion of the tumourcells exceeded 75%. As mentioned earlier, 70 cases were
ERa+ and the remaining 30 were ERa- by immunohistochemistry. House-keeping
genes, hypoxanthine-guanine phosphoribosyltransferase (HPRT) and
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) were measured to assess the
quality of the tumour sample cDNA. Oestrogen receptor alpha (ERa), Oestrogen
receptor beta (ERB) isoforms ERB1, ERB2 and ER§S5, and deletion variants ERBAS
and ERBA3 were fully quantitated by real-time, polymerase chain reaction (PCR).
Their expression levels were compared with other standard parameters and used in
survival analysis for better understanding of these molecular markers.
4.2 Optimization of mRNAassays
Standard protocols and primers were available to perform quantitative PCR for ERa,
HPRT and GAPDH genes (Dr Michael Davies, personal communication).
Quantitative PCR was performed in duplicate on a Bio-Rad Icycler Real-Time PCR
machine (Bio-Rad Laboratories Ltd., Hertfordshire, U.K.). Expression levels of
mRNA for each gene were calculated using standard curves produced with the
relevant cloned cDNAsbytrying various dilutions and temperature settings. Optimal
conditions were selected on the basis of sensitivity and reproducibility of these
standard curves. The PCR mix andthe protocol are detailed in the Methodssection.
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For ERB1, ERB2, ERB5, ERBAS and ERBA3 primers were previously validated
(Critchley et al, 2002; Poola, 2003). All the primers wereinitially evaluated using
different temperature conditions and PCR mixes (e.g. varying primer concentration
and MgCl, concentration). The optimal conditions and primers which gave unique
bands were then used to evaluate these variants in the breast tumour samples (Table
2.2). Testis, prostate and uterus RNAswere used as controls in each PCR experiment
as a quality control reference. Each tumour was amplified at least in duplicate and
the mRNAlevel was taken as the average from any positive sample. If there was no
amplification in both duplicates, the mRNA expression was inferred as absent.
Identity of PCR products were confirmed by agarose gel electrophoresis (Figure 2.2),
cloning, DNA sequencing and BLASTsearching via the NCBI website (Figures 2.4
and 2.5).
4.3 Measurement of ERa mRNA
ERa mRNAexpression was noted in all except three samples irrespective of ERa
immunostatus. The mRNA level ranged between 0.03 attomoles per ug total RNA
and 257 attomoles per pg total RNA. There was good correlation between ERa
immunostaining and mRNA expression (%+ cells, Pearson=0.308 P=0.002;
Spearman=0.480 P<0.001) across the whole cohort (Figure 4.1); but the significance
was lost whenthe correlation was limited to 70 ERa+ cases (Pearson=0.151 P=0.23;
Spearman=0.145 P=0.25). Mean ERa mRNAlevel wassignificantly high (P=0.006
T-test, P<0.001 MW) in ERa+tcases (mean 33 attomoles per pg total RNA) than
ERa- cases (mean 51 attomoles per jg total RNA) as one would expect. The three
cases which did not express mRNA were all ERa- by immunohistochemistry.
4.3.1 Correlation with clinicopathological characteristics
There was nocorrelation of ERa mRNA expression with tumoursize, nodalstatus,
vascular invasion and invasive ductal carcinoma, but there was a correlation with
grade (Spearman P=0.001) and ERa mRNA expression wassignificantly high in
low-grade tumours (MW P=0.001) (Figure 4.2.A).
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ERa mRNA levels correlated with PgR immunostaining (Y%+ve cells, Spearman
P<0.001) and were higher in PgR+ tumours (MW P<0.001), although mean levels
were not significantly different between in PgR+ and PgR-cases (T test P=0.29).
Whenthe analysis was limited to 70 ERa+ cases, there was no correlation between
ERa mRNAexpression and other standard parameters. The differential expression
noted in low grade and PgR+ tumourswasalso no longer evident.
4.3.2 Correlation with survival status
First a ROC curve was obtained to identify the optimal cut-point for ERa mRNA
values using breast cancer 5-year relapse. The area under the curve was 0.67 (CI
0.56-0.78) and the P value was 0.007 (Figure 4.12A). The optimum mRNAcut-off
point was 8 attomoles per pg of total RNA. In Kaplan Meier survival analysis, using
this cut-off value, the ERa mRNA values above the cut-off was significantly
associated with good outcome in the 100 cohort group [RFS Log Rank P=0.029,
BCS Log Rank P=0.01 (Figure 4.3)]. Similar good outcome wasalso noted in Cox
univariate analysis (RFS HR=2.08 CI 1.06 to 4.06 P=0.03, BCS HR=2.78 CI 1.23 to
6.29 P=0.01). In multivariate analysis of ERa protein and mRNA, only ERa immuno
status retained its significant association with outcome in RFS (Cox P=0.011)
whereas ERa mRNAwasthe strongest in BCS (Cox P=0.014). In the 70 ER+ cohort,
there was norelation between ERa mRNAand outcome as one would expect.
4.4 ERB1 quantitative assay
ERB1 was detected in 84 tumour samples and in the remaining 16 cases it was below
the limit of detection. The mean ERB1 mRNAexpression was 0.00084 attomoles per
ug total RNA. ERB1 mRNAlevel wassignificantly higher in ERa+ cases than ERa-
cases (T test P=0.002; MW P<0.001). The mean ER#1 level in ERa+ case was
0.0011 attomoles per ug total RNA and in ERa- case was 0.00015 attomoles per pg
total RNA, a fold difference of 7.3. The ERa mRNA level is approximately 1000
times higher than ERB1 mRNA level across the whole cohort (Paired T test
P<0.001).
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4.4.1 Correlation with clinicopathological characteristics
ERB1 mRNA level correlates with ERa+ staining (%+ cells, Pearson P=0.008)
(Figure 4.4) and there was a trend for PgR staining (%+ cells, Pearson P=0.057),
with ERB1 mRNA level significantly higher in PgR positive tumours (T test
P=0.041; MW P=0.042). ERB1 mRNAcorrelates inversely with grade of the tumour
(Spearman P=0.001), being significantly higher in low grade tumours (T test
P=0.016; MW P=0.005) (Figure 4.2.B).
There was no significant relationship between ERBlmRNA and tumoursize,
histological type, vascular invasion or nodal status.
4.5 ERB2 quantitative assay
ERB2 mRNAwasdetected in all tumour samples. The range of mRNA level was
between 0.00018 and 0.025 attomoles per pg total RNA. There was nosignificant
difference in expression levels between ERa+ and ERa- tumours (%+ cells, Pearson
P=0.386) (Figure 4.4). The ERB2 mRNA level wassignificantly lower than ERa
mRNAlevels (Paired T test P<0.001).
4.5.1 Correlation with clinicopathological characteristics
There wassignificantly higher expression of ERB2 mRNAinhistological types other
than invasive ductal carcinoma (MW P=0.044) and a trend for low expression in
tumours with lymphovascular invasion (MW P=0.061). There was no significant
relationship between ERB2mRNAand ERastatus, PgR status, tumoursize, grade
and nodalstatus.
4.6 ERB5 quantitative assay
ERB5 mRNA was expressed in all 100 cases. The range is between 0.000092
attomoles per pg total RNA and 0.040 attomoles per tg total RNA. The mean ERB5
mRNAlevel was 0.0050 attomoles per pg total RNA. ERBS mRNA levelcorrelates
inversely with ERa staining (%+ cells, Pearson P=0.001; Spearman P<0.001) (Figure
4.4) and PgR staining (%+ cells Pearson P=0.013; Spearman P=0.030). The mean
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ERB5 mRNAlevel was significantly higher in ERa- cases compared to ERa+ cases
(T test P<0.001; MW P=0.001; Paired T test P<0.001) and in PgR- cases compared
to PgR+ cases (T test P=0.029; Paired T test P<0.001).
4.6.1 Correlation with clinicopathological characteristics
There was no significant correlation between ERB5 mRNA and tumoursize, grade,
invasive ductal carcinoma, lymphovascular invasion and nodal status.
4.7 ERBA5 and ERBA3 quantitative assay
ERBAS mRNAwasonly detected in 20 cancers, 17 of which were ERa- and 14 of
them were high grade tumours. The mean value was 0.000028 attomolesper 1g total
RNA. ERBA3 wasonly detected in 2 cases, one was ERa- and the other was ERa+,
and both were positive for ERBAS.
4.7.1 Correlation with clinicopathological characteristics
ERBASpositive status was associated with ERa negative status (P< 10° Chi-square),
levels were higher in ERa- cases (P=10° MW)andthere was significant inverse
correlation with ERa staining (P< 0.0002 Pearson). Similar associations were seen
between high ERBAS and PgR negative status (P=0.009 Chi-square, P=0.007 MW)
and there was a significant inverse correlation with PgR immunostaining (P=0.023
Pearson). ERBAS positive status was also associated with high grade (P=0.005 Chi-
square, P=0.002 MW) andthere wasa significant positive correlation with grade
(P=0.006 Spearman).
Further investigation indicated an association with p53 mutation (Chi-square 7.71
P=0.006) andproliferation, as measured by Ki67 (Chi-square 3.99 P=0.046). ERBAS
positive samples had significantly high expression of Ki67 (% + cells P=0.002 MW)
with mean number of Ki67 positive cells (49%) being higher than in cases negative
for ERBAS (21%, P=0.000004 T test). [Ki67 expression data and p53 mutation data
were obtained from CTBRC; Ki67 data (n=19) was kindly provided by O’Neill efai.
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and has been published previously (O’Neill et a, 2004).);53 mutation status (n= 20)
was kindly provided by Innes et al. (Innes, MD Thesis, University of Liverpool,
2004) and is based on sequencing of PCR products covering the coding region of the
TP53 gene.| There was no association with histology, size and vascular invasion.
There wasno association with histology, size and vascular invasion.
4.8 Comparison of expression of ERB1, ERB2, ERB5, ERBAS and
ERBA3 mRNA
Mean levels of ERB1 (0.0008 attomoles per pg total RNA) were significantly lower
(P< 107° paired T-test) than either ERB2 (0.006 attomoles per pg total RNA) or
ERB5 (0.005 attomoles per pg total RNA), but there was no significant difference in
mean ERB2 and ERBS mRNAlevels (Figure 4.5).
ERR variant mRNAsweredifferentially expressed in the ERa+ and ERa- tumours; in
ERa+ cases ERB2 was expressed at the highest level followed by ER®5 then ER#1,
but in ERa- cases ERB5 was the highest followed by ERB2 then ERB1 (Figure 4.5).
Mean ERf1 levels were significantly higher in ERa+ cases than ERa- cases
(P=0.002 T-test, P=0.0001 MW), but mean ERB5 levels were significantly lower in
ERa+ cases (P=0.0004 T-test, P=0.001 MW). In the full cohort (n=100), ERB2
mRNAlevels correlated positively with ERB1 mRNA(Pearson 0.36, P=0.0003) and
to a lesser extent with ERB5 mRNA (Pearson 0.22, P=0.025), but there was no
significant correlation between ERB1 and ERB5 (Pearson 0.08, P=0.42) (Figure 4.6).
However, within the ERa+ cohort (n=70), levels of mRNA for all C-terminal
variants correlated with each other (P< 0.005 Pearson).
There was a significant positive correlation of ERBAS mRNA with ERB2 (P=0.02
Pearson) and ERB5 (P< 0.0005 Pearson) mRNA,andpositive correlations with grade
(P=0.006 Spearman), but no significant correlation with ERBl mRNA. ERBAS5
expression could not be accounted for by deletion within ERB alone. In a significant
proportion of cases the measured amounts of ERBAS was greater than that of ERB1
(Figure 4.7), but could be accounted for if a proportion of ER®2 and/or ERBS5
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mRNAsalso contained deletions of exon 5. Preliminary work to detect such complex
variants (data not shown) indicates that they do exist.
4.9 Association of ERB1, ERB2, ERB5, ERBAS and ERBA3 mRNA
with patient survival
Using ROC-derived optimal cut points for the 100 case (ERa+ and ERa-) qRT-PCR
cohort in Kaplan Meier Log Rank analysis, there were relationships between higher
ERisoform expression and good outcome for ERB1 (P=0.065 RFS, P=0.047 BCS;
Figure 4.8), ERB2 (P=0.046 RFS, P=0.042 BCS; Figure 4.9) and ERBS (P=0.028
RFS, P=0.023 BCS; Figure 4.10).
In the ERa- cases, high ERB5 mRNA wasassociated with better outcome (RFS
P=0.008 Log Rank, HR 0.25 CI 0.08-0.75 P=0.014; BCS P=0.066 Log Rank, HR
0.33 CI 0.097-1.14 P=0.080; Figure 4.11). The 5 year cumulative relapse-free
population was 59% in the ERBS-high group (n=23) compared to 0% in the ERBS-
low group (n=6); the 5 year cumulative BCS was 67% in the ER$5-high group
(n=23), compared to 40% (n=5) in the ERB5-low group. Noassociations were found
between other ERB isoform mRNAlevels and outcome in this (admittedly small)
cohort. Only nodal status was also significantly associated with poor outcome in
these ERa- cases (RFS P=0.024 Log Rank, HR 2.9 CI 1.1-7.7 P=0.031). There was
no association between ERBS and nodal status (P=0.77 Chi-square) and in
multivariate analysis high ERB5 mRNA wasassociated with better outcome (RFS
HR 0.21 CI 0.06-0.82 P=0.024) independent of nodalstatus.
Further outcomeanalysis for ERB splice variant mRNA waslimited to ERa positive
women who received adjuvant tamoxifen and had a defined breast cancer related
outcome (n=62 RFS, n=58 BCS). High grade (RFS P=0.006, BCS P=0.0008) and
positive nodal status (RFS P=0.003, BCS P=0.007) maintained their association with
worse outcome (Log Rank). ROC plots indicated a significant relationship between
good outcome and high qRT-PCRvalues for ERB2 (RFS area under curve 0.68 CI
0.52-0.84, P=0.036) (Figure 4.12) and ERB5 (RFS area under curve 0.68 CI 0.54-
0.83, P=0.033). Optimal cut-points for qRT-PCR data determined by ROCanalysis
for RFS and BCS at 5 years were 0.00068 (ERB1), 0.00393 (ERB2) and 0.00224
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(ERB5) attomoles per ug total RNA. Significant relationships were found between
the subsequent dichotomized qRT-PCR categorizations and good outcome for both
ERB2 and ERBS5,but not ERB1 (Figure 4.13).
High ERB2 mRNA wasassociated with better outcome (RFS P=0.0095 Log Rank,
HR 0.32 CI 0.13-0.79; BCS P=0.011 Log Rank, HR 0.25 CI 0.08-0.79) and a similar
relationship was seen with ERB5 (RFS P=0.06 Log Rank, HR 0.44 CI 0.19-1.06;
BCS P=0.018 Log Rank, HR 0.28 CI 0.09-0.85). These variables exhibited a
significant association with each other (P=10° Chi square, P=0.001 Pearson) and
were highly concordant (81% of cases), but in multivariate analysis ERB2 emerged
as the strongest marker for both RFS and BCS. The 5 year cumulative relapse-free
population was 81% in the ERB2-high group (n=30) compared to 55% in the ERB2-
low group (n=32); the 5 year cumulative BCS was 89% in the ERB2-high group
(n=29), compared to 62% in the ERB2-low group (n=29).
When grade, size, nodal status and PgR status were included in Cox multivariate
analysis of the ERa+ tamoxifen-treated cohort, high ER®2 had independent
significance for good outcome: for RFS, ERB2 (HR 0.31 CI 0.11-0.86, P=0.024) and
nodal status (HR 3.7 CI 1.2-11.5, P=0.022) were independently significant; for BCS,
ERB2 (HR 0.17 CI 0.05-0.65, P=0.0095) and grade (HR 1.8 CI 1.03-3.3, P=0.041)
were independently significant. Notably there was no significant association between
ERB2 and grade, size, nodal status or PgR status in this treatment-specific cohort (all
P> 0.35 Chi-square).
In ERa-+, node negative cases (n=33), using a lower cut-off (0.00185 attomoles per
ug total RNA) defined by ROCanalysis of this subgroup, ERB2 wassignificantly
associated with better outcome (RFS P=0.0005, BCS P=0.00002 Log Rank) (Figure
4.14); the 5 year cumulative relapse-free population was 96% in the ERB2-high
group (n=26), compared to 39% in the ER®2-low group (n=7) and the 5 year
cumulative BCS was 95% in the ERB2-high group (n=25), compared to 27% (n=6) in
the ERB2-low group.
ERBASpositive status was not associated with RFS or BCS.
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4.10 Discussion
4.10.1 Optimisation and choice of assay
ERa, ERB1, ERB2, ERB5, ERBAS and ERBA3 mRNAs were measured fully
quantitatively with standard curves prepared from known quantities of respective
cloned cDNAs.This technique allows us to measure the absolute starting quantity of
mRNAsin attomoles and also showsobjective evidence of PCR efficiency and the
range over which the assays are valid. This makes comparison between assays or
different genes easier and more reproducible. In most of the previous studies mRNAs
were evaluated either relatively using the AAct method (which can introduce bias as
it usually assumes equal PCRefficiencies) or semi-quantitatively by measuring the
intensity of fluorescence of gels of PCR products (which has a limited dynamic
range).
The limitation of measuring genes by qRT-PCR is that it may measure RNA
molecules from epithelial cells as well as stromal cells, fibroblasts and endothelial
cells. It has been well proved that ERB is expressed in comparatively larger amount
than ERa in stromal cells, fibroblasts and endothelial cells (Speirs et al, 2002).
Hencepart of the expression level seen may be due to non tumourcells.
HPRT and GAPDHwere measuredto validate the quantity and quality of the RNA,
and account for differences in cDNA synthesis. Their levels were used to normalize
the candidate gene expression bya factor relative to the mean of expression over the
cohort. Use of 2 control genes minimizes bias due to either one. Positive controls
(RNA from testis, ovary and prostate and MCF7 cells) and negative controls (no
cDNAin the PCR or noreverse transcriptase in cDNA synthesis reactions) were
used in each PCRfor quality control and to rule out genomic DNA contamination.
Variant specific primers were used for candidate genes to measure the mRNA. To
maximize specificity and sensitivity of detection, and make correlation with other
markers more relevant, PCR conditions were optimised and PCR product identity
was confirmed by gel electrophoresis and DNA sequencing. For ERB2 this was
particularly important as primer design was limited by the sequence overlap between
ERB2 and ER§5; it was achieved by shortening the extension time in the PCR to
favour the shorter PCR product.
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4.10.2 ERa mRNA qRT-PCR
ERa mRNA wasquantifiable in 97 cases out of 100 patients, which includes 27 ERa
negative patients. The 3 cases which were negative were ERa negative by
immunohistochemistry. There was a 10,000 fold difference between low and high
ERa mRNA levels, which is a wider range than seen for most genes, including the
ERBvariants. There was goodcorrelation with ERa immunostaining, which confirms
utility of qRT-PCR, suggests that the RNA samples were broadly representative of
the tumour cell populations scored by immunohistochemistry and indicates the
importance oftranscriptional control mechanism in determining ERaprotein levels.
Ofnote, the expression of the ERa immunostaining is usually bimodal (Collinset al,
2005) compared to the broader distribution of ERa mRNAexpression seen in our
study. It is possible that this bimodal distribution may due to some post
transcriptional control, combined with a narrower dynamic range for immunostaining
compared to qRT-PCRanalysis.
The correlation of ERa mRNA with PgR status and low grade tumour across the
whole cohort mirrors that of ERa protein expression. This again suggests that total
RNA samples were representative of the tumour sections for immuno. That these
correlations with grade and PgR were lost when considering the ERa positive cohort
is most likely due to exclusions of the more extreme cases with lowest levels of ERa
mRNA, which are also lowest for PgR and of generally higher grade, hence
narrowing the range over which correlations were assessed.
The dichotomized ERa mRNA level showed good correlation with survival, as
expected from its association with ERa immunostatus. In multivariate analysis,
compared to immuno status ERa mRNA wasa better marker for BCS (although not
for RFS). Such results are unlikely to influence the current clinical practice of
measuring ERa by immunohistochemistry.
4.10.3 ERB1, ERB2 and ERB5 mRNAassay
Comparison of the mRNAresults presented with those of othersis difficult as not all
studies have been as thorough in terms of specificity of their primer design or their
quantification methodology.It is also possible that others may have underestimated
ERB mRNAlevels by using assays of insufficient sensitivity. Extra care needs to be
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taken when detecting ERB mRNA, which is shown bytheir greatly reduced range
and level of expression compared to ERa, as demonstrated quantitatively here.
Many early studies used PCR primers designed to differentiate between ERa and
ER§, which did not take into account ERB C-terminal variants or deletion variants,
as they were unknown at that time. Our results indicate that the mRNA levels of
ERB2 and ERBS5 often exceed that of ERB1; hence, many early studies could have
overestimated “ERB” expression by measuring total ER®. The level of expression of
exon deletion variants measured here indicate that they are unlikely to impact on
measurement of ERB, being expressed at relatively low levels and detected in a
minority of cases.
In studies of ERB C-terminal variants, many studies utilized variations of the “triple
primer” assays (Iwao eft al, 2000; Omoto ef al, 2002) to detect ERB1, ERB2 and
ERBS5 by means of agarose gel electrophoresis. Despite careful optimization and
validation by some, this assay has limited dynamic range and suffers from primer
competition (where multiple variants compete for primer usage in the PCRreaction).
Perhaps more importantly, for assessing the importance of ER variants with
outcome, the semi-quantitative approaches do not lend themselves to assessment of
optimal cut-points for use in grouping, as required for survival analysis when limited
numbersof cases are available for study.
In this study, ERB variants were expressed much lower than ERa (1000 times lower
for ERB1 and 100 times lower for ERB2 and ERB5) as previously reported (de
Cremoux et al, 2002; Speirs et al, 1999a). This low expression of ERB mRNA was
also noted in situ hybridisation studies (Sasano ef al, 1999), ERB2 and ERBS were
expressed at detectable levels in all tumours, and wild-type ERB1was expressed in
84% of cases. More interestingly ERB2 and ERBS mRNAlevels were significantly
higher than ERB1 in individual samples, as previously reported (Leygue ef al, 1999;
Omotoet al, 2002). This may be due to ERB1 down regulation in tumours compared
to normal tissue (Shaaban et al, 2003), although we have not measured ERB1 in
matched normaltissues to support this hypothesis. Omotoef al. compared the mRNA
of ERB1 and ERB2 by RT-PCRin breast cancers and adjacent normal breast tissues
in 22 cases and found that ERB1 level is lower and ERB2 level is higher in cancers
compared to the normal breast tissues (Omoto et al, 2002). Iwao et al. found both
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ERf1 and ERB2 higher and ERB5 lower in normal tissues comparedto breast cancers
by triple-primer PCR assay in 112 cancers and 11 adjacent normal tissues (Iwao ef
al, 2000). ERBS was more abundantly expressed in ERa- cases and this was seen
previously in a cohort containing both Caucasians and African American patients
(Poola et al, 2005b). These results indicate that rather than the expression of total
ERbeingaltered, individual splice variants may be downregulated or upregulated in
tumourigenesis.
In this study, ERB2 did not show any association with ERa. However, ERB1
positively correlated with ERa and to a less extent with PgR, with significantly high
ERB1 in ERa+ and PgR+ cancers. On the contrary ERB5 inversely correlated with
ERa and PgR, with significantly high ERBS in ERa- cancers. This again showsthat
ERB1 and ERB5 showing different association with ERa status and this may be due
to different transcriptional/epigenetic control. These findings were not consistent
with the study of Poola et al. (Poola et al, 2005b), who quantitatively measured
ERB1 and ERB2 in 60 ERa- (20 Caucasians and 40 African Americans) and 74 ERa+
(34 Caucasians and 40 African Americans) breast cancers. There was nosignificant
difference in mRNAlevels of ERB1 and ERB5 in ERa positive or negative patients
in their study. This can partly be explained by the case selection, as the study did not
comment on the menopausal status of the patients and, also ERa positivity was
estimated by immunohistochemistry in some patients with cut off for positivity at
>5% and in the remaining patients ERa+ status was determined by ligand binding
assay. In ourstudy, all patients were postmenopausal and ERa status was determined
by immunohistochemistry with 10% cut off value, as universally accepted. Another
factor to consideris the ethnicity of the patients investigated. Their cohort is made up
of Caucasians (Americans) and African Americans, ours was mainly Caucasians of
British origin. ERB expression profile differs in various ethnic groupsas seen in their
study as well as other studies (Poola et al, 2002c). These differences may explain the
discrepancies in the expression levels of ERB1 and ERS in the above study. Another
study (Iwao ef al, 2000) used triple-primer PCR assay to measure ERB1, ERB2 and
ERB5 in 112 cancers (both premenopausal and post menopausal) and found no
significant difference in the proportion of ERB variant expression between ERa+ and
ERa- patients. However when they measured the ERB mRNA using g-RTPCR
method using primers located in exon 5 and 7 in the same cohort of patients, ERB
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mRNAlevels were significantly higher in ERa- breast cancers than ERa+ (Iwao et
al, 2000). Again this Japanese study had different case selection and different PCR
techniques and different ethnic population, which may have contributed to the
difference in expressionlevels.
The variants were differentially expressed; in ERa+ cases, ERB2 was highly
expressed followed by ERB5 and ERB1. In ERa- cases, ERB5 is highly expressed
followed by ERB2 and ERB1. ER®2 correlated with the others, but ERB1 and ERB5
did not correlate with each other in the whole cohort, although they correlated with
each other in the ERa+ cohort. Hence it would seem that ER C-terminal splice
variants are differentially regulated and in ERa- cases in particular there is a clear
difference in the transcriptional control of ERB1 and ERB5.
ERB1 correlated positively and ERB5 inversely with ERa status and PgR in our
study. This is interesting as studies by semi-quantitative PCR for ERB have shown
inverse correlation with PgR (Cullen et al, 2001; Dotzlaw et al, 1999) or no
correlation (de Cremoux eft al, 2002). Similarly for ERa there was positive or
negative correlation (Bieche ef al, 2001; Knowlden et al, 2000; Kurebayashief al,
2000) and no correlation (de Cremouxet al, 2002; Dotzlaw et al, 1997) with ERB
mRNA. From our study, investigating individual variants in a fully quantitative
manner has shown differential expression of the individual variants in tumours
depending upon their ER/PgR status (ERB1 positive correlation, ERB2 no correlation
and ERB5 negative correlation). The above studies measured the total ERB and,
depending upon the location of their primers, this may have influenced the
proportional amount of these variants and may have resulted in spurious values
resulting in this discordant association with ER/PgRstatus.
ERB1 is the only variant showingassociation with low grade tumourssimilar to ERa.
Sugiura ef al. evaluated ERB1 and ERB2 mRNAin fully quantitative manner in 150
cases (ERa+ and ERa-) by qRT-PCR and found both correlated with each other
similar to our study. ERB 1 also positively correlated with PgR status and low tumour
grade while ERB2 did not correlate with any standard clinicopathological parameters
similar to our study. Interestingly, the ERB1 and ERB2 mRNAexpression correlated
with respective protein expression as well (Sugiura ef al, 2007).
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Leygueet al. evaluated ERB1, ERB2 and ERBS5 bythe Triple primer-PCR technique
in 53 breast cancers. ERB1 correlated inversely with tumour grade while ERB2 and
ERB5correlated positively (Leygueet al, 1999).
However most of the ERB RNAstudies using quantitative or semi-quantitative,
specific or non-specific primers have not shown any association with tumour grade,
tumour size and nodalstatus (Bieche ef al, 2001; Cullen et al, 2001; de Cremoux et
al, 2002; Dotzlaw et al, 1999; Iwao et al, 2000). One RT-PCR study evaluated ERB
with primers in the N terminal region in 60 breast cancers and found association
between ERa+/ERB+ status and, node positivity and high grade tumours (Speirs ef
al, 1999a). Again this observation was seen in a relatively small cohort using non-
specific primers measuringall the variants and this may explain the association with
poor prognostic markers not seen by others.
4.10.4 ERBA5 and ERBA3 mRNAassay
Deletion variant ERBA5 positivity was associated with high grade tumours and this
was previously noted in a study of 43 breast cancer patients of both premenopausal
and post menopausalstatus (Poola et al, 2002b).
Another significant finding in this study is the disparity in the amounts of ERBAS
and ERB1 (10 out 20 cases expressing higher levels of ERBAS than ERB1) which
supports the notion that ERB2 or ERS variants can also harbour exon deletions. As
exon 5 deletion leads to a functionally distinct truncated protein not detectable with
the reagents used, in theory this could explain some of the discrepancy between
ER§2 protein and mRNA.This would only be relevant to the small numberof cases
in which mRNAlevels were high when protein levels were low, and in all cases
ERBAS was only a minor component compared to the ERB2 mRNAlevel (Figure
4.7).
ERBA3 was detected in 2 cancers and both were positive for ERBAS. ERBA3
expression has not previously been reported in breast cancer (Herynk & Fuqua,
2004). Our study showsthat this variant may be expressed in breast cancer, but
rarely.
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4.10.5 ERB splice variants and outcome
All C-terminal variants (high expression as defined by ROC curve) showed
association with better outcome in the whole cohort, but in the ERa+ tamoxifen
treated cohort, ERB2 and ERBS were associated with better outcome in KM survival
analysis. In Cox multivariate analysis, ERB2 was the only variant independently
associated with better outcome (RFS and BCS). ERBAS positive status was not
associated with RFS or BCS, even though there was association with ERa and PgR
negative status, high grade tumours, high Ki67 expression and p53 mutation.
Aswith the investigation of clinical and biological correlations, many comparisons
between the present study and previous work are difficult due to the different
methods of assessments of ERB, most of which were either not variant specific or not
fully quantitative. Furthermore, it is in determining the relationship with outcome
that most studies fall short in terms of numbers studied and case selection. These
factors are closely linked, in that smaller studies of cases carefully matched for
treatment are more likely to provide relevant insight than the same size, or even
larger, studies in which treatment has not been taken into consideration. It is the
intention of treatment to affect an improvementin patient outcome, and the treatment
regime is often determined by the perception of risk of recurrence. Despite this,
many studies do not take in to account these clearly confounding factors andtry to
relate ERB expression in groups of patients receiving a variety of different
treatments. This is understandable given that clinical samples are often drawn from
limited retrospective cohorts, but requires that comparison between studies take into
accountthe possible selection biases.
Davies et al. (Davies et al, 2004) studied ERB1, ERB2 and ERBS mRNA in semi-
quantitative manner in a overlapping cohort of 105 patients (both ERa+ and ERa-)
and found association with better outcome for ERB2 and ERBS5 in whole cohort as
well as in the ERa+ subgroup. ERB1 was not associated with outcome. The present
study done in fully quantitative manner showed outcomeresults similar to the semi-
quantitative data for ERB2 and ERB5. However, ERB1 showed association with
better outcomein the whole cohort (ERa+ and ERa-) and this association waslost in
the ERa+ cohort. By fully quantitating, and assigning cut-points with ROC curve
analysis, association with outcomeis better demonstrated in this study.
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The advantage of our study is that all patients received adjuvant endocrine treatment
and 93 patients (63 ERa+ and 30 ERa-) received tamoxifen only. Our outcomeresult
can also be taken as a surrogate marker for tamoxifen responsiveness/resistance in
our cohort. Murphy ef al. measured ERB1, ERB2 and ERBS mRNA in semi-
quantitative mannerin a cohort of 27 node negative ERa+ patients who were either
sensitive or resistant to tamoxifen and found nosignificant difference in their levels
in these two groups (Murphyef al, 2002). Changef al. estimated ERB mRNAby RT-
PCR in 30 cancers (21 sensitive to tamoxifen and 9 resistant) and the ERB mRNA
level were high in the resistant group with marginal significance (Fisher’s exact test
P=0.11) (Changet al, 2005). Speirs et al. semi-quantitatively measured ERB mRNA
in a small cohort of 17 patients who either responded or wereresistant to tamoxifen,
and found higher ERB mRNAin tamoxifen resistant group (Speirs et al, 1999a).
Cappelletti et al. evaluated ERa and ERB mRNA with RT-PCR, pre and post
treatment, in a cohort of 47 patients who received neo-adjuvant toremifene for three
months. There was no significant correlation with endocrine response to tumour
(shrinkage) or pre and post ERB mRNAlevel. In contrast ERa mRNA washigh in
tumours which responded to treatment and their level was downregulated after
treatment (Cappelletti et al, 2004). These four mRNA studies either showed no
relation or poor correlation with outcome in endocrine treatment setting. However
the cohorts were small and different endocrine regime and different PCR assessment
methods were used, makingit difficult to come to a meaningful consensus.
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Figure 4.1 Scatter plot of ERa mRNA expressionin relation to ERa protein expression.
Markersare coloured according to ERa immunestatus.
Green = ERa positive cases.
Blue = ERa negative cases.
Line represents linear regression for all cases.
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Figure 4.3 Kaplan Meier survival plots RFS (A) and BCS (B) for ERa mRNA
dichotomized by ROC cut-point as high and low. High ERa mRNA levels were
associated with better outcome.
Green line — high mRNA;Blue line — low mRNA
Crosses on the lines represent censored data.
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Figure 4.4 Scatter plots of ERB variant mRNA expression in relation to ERa protein
expression. ERB1 showed a positive association with ERa protein expression, whereas
ERBS5 showeda negative association and ERB2 showednoassociation.
Markers are coloured according to mRNA level (dichotomized by respective ROC cut points
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cases.
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Figure 4.8 Kaplan Meier survival plots for RFS (A) and BCS (B) for ERB] mRNA
dichotomized by ROC cut-point as high and low in the whole cohort. High ERB] mRNA
levels were associated with better outcome.
Greenline — high mRNA;Blue line —- low mRNA
Crosses onthe lines represent censored data in the whole cohort
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Figure 4.9 Kaplan Meier survival plots for RFS (A) and BCS(B) for ERB2 mRNA
dichotomized by ROCcut-point as high and low in the whole cohort. High ERB2 mRNA
levels were associated with better outcome.
Greenline — high mRNA;Blue line —- low mRNA
Crosses on the lines represent censored data
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Figure 4.10 Kaplan Meiersurvival plots for RFS (A) and BCS (B) for ERB5 mRNA
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Figure 4.14 Kaplan Meiersurvival plots for RFS (A) and BCS(B) for ERB2 mRNA
dichotomized by ROCcut-point as high and low in the ERa+ node negative tamoxifen
treated cohort. High ERB2 mRNAlevels were associated with better outcome.
Green line — high mRNA;Blue line — low mRNA
Crosses on the lines represent censored data
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CHAPTER 5 RESULTS3
ERB2 IMMUNOHISTOCHEMISTRY ESTIMATION AND
ANALYSIS
5.1 Introduction
Biomarkers can make use of measurements of MRNAlevels, but a functional role for
ERB variants in breast cancer is more heavily suggested by expression of the
corresponding protein. Furthermore, immunohistochemical assessment is more
commonly usedin theclinical setting for prognostic and predictive purposes(e.g. ER
and PR). Therefore, as ERB2 mRNA emerged as the most significant marker for
outcome and suitable reagents became available, expression of ERB2 protein was
assessed in order to address its relationship to mRNA expression as well as to
treatment outcome.
5.2 ERB2 Immunohistochemistry
A cohort of 141 cases were analysed by immunohistochemistry for ERB2 (Table 3.1)
including 98 ERa+ cases. ERB2 staining was assessed by 2 observers (R.V., V.A.)
using the Allred scoring system andalso as percentage positive cells (Yo+), with good
agreement between observers (Allred Spearman 0.91 P = 1.0 x 10°, %+ Pearson 0.92
P=3.4 x 10°»), At the cut-point used for outcome analysis the Kappa score was 0.87.
A consensus score was produced and used herein. The frequencies of each score
weredetailed in Table 5.1 and representative examples of immunostaining are shown
in Figure 5.1.
5.3 Correlation with clinicopathological characteristics
ERB2 immunostaining significantly correlated with that for ERa both for %+ cells
(Pearson 0.42 P=7.8 x 10’) and for Allred score (Spearman 0.40 P=4.1 x 10°). ERB2
immunostaining was greater in ERa+ cases (mean %+=69) than in ERa- cases (mean
%+=52) and this difference wasstatistically significant (P=0.00001 T-test). ERB2
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immunostaining also correlated, to a lesser extent, with PgR (%+ Pearson 0.18
P=0.035) and ERB2 Allred score was greater in PgR+ cases than PgR- cases
(P=0.033 MW). The percentage of ERB2 positive cells were somewhat lower in
grade 3 cases (P=0.042 MW), in keeping with the association with ERa status. There
was no association with vascular invasion, nodal status, age or size, or with ERB1-
specific immunostaining (ERB1 immunohistochemistry data was available for 82
cases from CTBRC).
5.4 Association of ERB2 protein with patient survival
Using the Allred scoring system, two groups of patients were designated as ERB2
low (score 5 or lower, n=41, 29%) and ERB2 high (score 6 or higher, n=100, 71%).
The cut-point used was that indicated by ROC curve analysis and confirmed by
testing of the limited number of possible groupings provided by the Allred scoring
method. Similar dichotomization was provided by a cut-point of 65% for proportion
of immuno-positive cells, but in keeping with published recommendations (Carder et
al, 2005), the Allred score was used predominantly for further analysis as it also
takes staining intensity into account.
The high/low ER®2 Allred score groups were significantly associated with ERa
status (P=0.001 Chi square) and within the subgroup of ERo positive women who
received adjuvant tamoxifen (n=85) there were 18 ERB2 low cases and 67 ERB2
high cases (79%).
Within the group as a whole (ERa+ and ERa- cases), high ERB2 protein levels were
significantly related to a better relapse free survival (RFS P=0.049 Log Rank), but
not for breast cancer survival (BCS P=0.16 Log Rank). However, in both cases the
survival curves converge at later time-points (Figure 5.2). With shorter follow-up
time a stronger relationship with outcome wasseen: e.g. at 5 years for relapse (RFS
P=0.018 Log Rank, HR 0.50 CI 0.27-0.90 P=0.020) and 7 years for survival (BCS
P=0.048 Log Rank, HR 0.50 CI 0.27-0.90 P=0.020). If ERa status and ERB2
immunoscore were combinedin multivariate analysis of 5 year RFS, only ERa status
was independently significant (HR 0.38 CI 0.22-0.66 P=0.001) whereas ERB2 did
not retain independent significance (HR 0.76 CI 0.43-1.33 P=0.33). With the
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addition of further parameters of grade, size and nodal status, only nodal status (HR
3.1 CI 1.5-6.2 P=0.001) and grade (HR 1.5 CI 1.1-2.2 P=0.026) were independently
significant.
When considering only ERa+, tamoxifen-treated cases there was no relationship
between ER$2 immunostaining and outcome (RFS P=0.95, BCS P=0.65 Log Rank)
(Figure 5.3).
5.5 Association between ERB2 mRNAandprotein
Whenassessingthe relationship between ERB2 immunostaining and mRNAlevelfor
paired samples from eachcase, no correlation was seen betweenlevels of protein and
mRNA for ERB2, by using %+ cells (Pearson 0.12 P=0.24) or Allred score
(Spearman 0.08 P=0.40). A similar lack of correlation was seen previously for ERB1
using semi-quantitative analysis of ERB1 mRNAin an overlapping cohort (O'Neill er
al, 2004); this was re-confirmed using quantitative ERB1 mRNA measurement in 82
patients from this study [Pearson (%+) 0.02 P=0.87; Spearman (Allred) 0.03
P=0.83].
However when ERP2 protein expression were dichotomized into high and low with
the cut off used for survival, patients with an Allred score of 5 or below (n=21) had
higher mean ERB2 mRNA than cases with an Allred score of 6 or more (n=79,
P=0.045 T-test), indicating a possible inverse relationship.
Using the cut-points optimized for outcome analysis, the majority of cases with high
ERB2 mRNAlevels also had high levels of ERB2 protein, but only a minority of
those cases with high ERB2 protein werealso classified as having high ERB2 mRNA
(Table 5.2). Hence, ERB2 mRNAexpression is frequently associated with expression
of significant levels of ERB2 protein, but ER®2 protein expression is often
dissociated from mRNA expression (being high in many cases with low mRNA
levels). Overall there is a subset of cases (35%) with concomitant high ERB2 mRNA
and protein, and another subset of cases (44%) in which high protein levels are
accompanied by low mRNAlevels.
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5.6 Association of ERB2 protein and mRNAwith patient survival
As discussed in the previous chapter ERB2 mRNA levels were associated with
outcomein univariate analysis in the whole cohort. Since high ERB2 protein levels
also showed better RFS in the whole cohort, they were entered into a Cox
multivariate model and they were independently associated with better RFS in the
whole cohort (ERB2 protein HR 0.40 CI 0.20-0.80 P=0.010, ERB2 mRNA HR 0.43
CI 0.22—0.83 P=0.013).
However, in the ERa+ tamoxifen-treated cohort, in multivariate analysis of mRNA
and protein, only high ERB2 mRNAlevels were significantly associated with lower
RFS (HAR 0.28 CI 0.212—0.72 P=0.008), but a trend remained for protein (HR 0.42 CI
0.15—1.19 P=0.10). Similar results were obtained for analysis of BCS.
Further outcome analysis was carried out in the 35% of cases with both high ERB2
protein and mRNAlevel; this group had a significantly better outcome than those
with low levels of either mRNAorprotein, and those cases with low levels of both
mRNAand protein had the worst outcome (RFS P = 0.009; BCS P=0.021 Log Rank,
Figure5.4). When cases with both high ERB2 protein and RNA were compared with
rest of the group consisting of all other cases, they had significantly better outcome
[(RFS P=0.002 Log Rank, HR 0.67 CI 0.51—0.88 P=0.004) (BCS P=0.003 Log Rank,
HR 0.61 CI 0.43—0.87 P=0.006)] (Figure 5.5). This association wasalso seen in the
ERa+ tamoxifen treated cohort [(RFS P=0.004 Log Rank, HR 0.61 CI 0.43-0.88
P=0.009) (BCS P = 0.009 Log Rank, HR 0.56 CI 0.34—0.91 P=0.020)] (figure 5.6).
The outcome benefit of concomitant high ERB2 mRNA and protein levels was
particularly markedat a shorter follow-up in the ERa+ tamoxifen treated cohort. This
measure was the only independent marker of improved outcome using Cox
multivariate analysis including grade, size, PgR status and nodalstatus at 5 years for
RFS (HR 0.48 CI 0.24—0.95 P=0.036) and at 7 years for BCS (HR 0.46 CI 0.23-0.92
P=0.029). In the ERa+ tamoxifen-treated, node negative cases, having both high
ERB2 mRNA andprotein wassignificantly related to an improved BCS (P=0.028
Log Rank).
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5.7 Discussion
As with mRNA measurement, many studies of ERB protein used antibodies that
targeted either N terminal epitopes which will potentially detect all the variants or C-
terminal ERB1-specific epitopes. So there were not manystudies specifically looking
for ER®2 protein. In considering the possible role of ERB2 protein, this discussion
will exclude ERB2 mRNAstudies, since mRNA cannot be taken as a surrogate
marker for protein expression.
5.7.1 ERB2 immunohistochemistry
Immunostaining is a technique which often varies between studies, due to the use of
different protocols, different antibodies and because some parameters (e.g. tissue
fixation) are beyondthe control of investigators using retrospective cohorts.
Here ERB2 immunohistochemistry was done with monoclonal antibody MCA2279S
(clone no 57/3; Serotec) which has been previously used by other studies (Saunders
et al, 2002) and wasthe reagent of choice in a subsequent larger study (Shaaban er
al, 2008). The method used was similar to other studies in terms of antigen heat
retrieval and overnight incubation of primary antibody at 4° centigrade, although the
former is sometimes difficult to replicate between laboratories as centres used
different heating methods: autoclave treatment for 7 minutes (Honmaef al, 2008),
pressure cooking for 15 minutes (Esslimani-Sahla et al, 2005) and microwaving for
15 minutes (Palmieri et al, 2004).
A blocking step was used to block cytoplasmic staining that was at the time
considered as non-specific, but some cytoplasmic staining remained as previously
noted with ERB (O'Neill et al, 2004; Shaaban er al, 2003; Skliris et al, 2003). Only
nuclear staining was includedin scoring, although subsequent studies (Shaabanef al,
2008) have indicated that cytoplasmic ER®2 staining might not only be real, but
might have biological significance. It would be interesting to see whether cases with
high mRNA and low protein in our study had significant cytoplasmic staining.
Additionally, it would be interesting to explore if the presence of cytoplasmic
staining is in any way related to the excess protein staining seen in a proportion of
cases with low mRNA.If this ERB2 protein that is not transcriptionally regulated is
stabilized in some way, it may be that it is detected in cytoplasm due to the cells
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having reduced ability to degrade it (which normally occurs in the cytoplasm).
Alternatively it may represent non-liganded ERs in cytoplasm, as ERs normally
reside in cytoplasm and undergonucleartranslocation after ligand binding (Leung er
al, 2006).
ER®2 staining was also noted in stromal and endothelial cells, as previously seen
(Esslimani-Sahla et al, 2005) and excluded from scoring. At present it is not clear
whether this non-epithelial ERB2 expression contributes to carcinogenesis or
hormone responsiveness. Interplay between epithelial and stromal cells is important
in breast development and it has been proposed that ERB2 mayplay a role in these
paracrine pathways.
Compared to ERastaining, which is usually bimodal in distribution, ERB2 staining
seems to be more varied and widely expressed by manycells. This makes assigning a
cut-point for ERB protein expression challenging, but is probably related to differing
biology of the two oestrogen receptors. ERa is usually highly expressed in only a
specific subset of normal breast epithelial cells, but is aberrantly expressed at these
same high levels in a larger proportion of cancerous breast cells in some cases of
breast cancer. In contrast ERB1 is more widely expressed in normalbreast epithelia
(Speirs et al, 2002), most likely at lower levels, and is lost in a more variable
proportion of cancer cells (Shaaban ef al, 2003). However ERB2 appears to be less
expressed in normal breast compared to DCIS andinvasive cancer (Esslimani-Sahla
et al, 2005), although no correlation between these two protein variants was evident.
Allred score and percentage of immunostaining were measured forthis study. Allred
score has been accepted as a standard measure for ERa (Leake ef al, 2000), as this
standardized approach also helps with correlation with other studies it has been
recommended for ERB (Carder et al, 2005). Some studies have used percentage
positivity alone (Esslimani-Sahla et al, 2004; Honmaef al, 2008) with a variety of
cut-off values.
In our study the cut-off was Allred score 5 or lower and 6 or higher. Using this cut-
off, 71% of cases had high ER$2 protein and 29% had low ERf2 protein. The
antibody dilution was 1 in 25 in this study. When higher dilutions were tried,
different positive values were observed and the consistency of staining was lost.
Other studies with the same antibody used dilutions of 1 in 10 (Shaaban et al, 2008)
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or 1 in 20 (Honmaef al, 2008). Shaaban ef al. reported 83% positive cases using a
20% cut-off and Honmaet al. reported 85% positive cases using a 10% cut-off.
Using these same cut-offs our positive cases would be 94% and 96% respectively,
indicating that our staining was stronger than reported elsewhere. Although these
studies used the same antibody, the antigen retrieval methods and incubation times
varied. These factors may have influenced the extent of staining reported here and
this is reflected in the higher cut-point chosen for outcomeanalysis. It is difficult to
assign a universal cut-off for ERB2 at this stage until the cut-off levels are validated
in large prospective studies and uniform protocols are accepted world-wide (Carder
et al, 2005).
5.7.2 Correlation with other clinicopathological characteristics
ERB2 protein expression correlates with ERa and PgRpositivity, and ER2 protein
was significantly higher in ERa and PgR positive cases. Similar to ERa there was
correlation with grade, as low levels of ERB2 were seen in high grade tumours. In
keeping with most previous studies there were no clear links to manyclinical and
pathological parameters.
Sugiura ef al. showed significant association in 150 patients between ERB2 protein
and ERa positivity and low tumourgrade similar to the current study (Sugiura ef al,
2007). In a large study by Shaaban et al. (757 patients), ERB2 protein expression
correlated positively with ERa, PgR and grade 2 tumours, and inversely with
vascular invasion and distant metastasis. Positive association was also seen with
androgen receptor and BRCA1 (Shaaban ef a/, 2008). In another large study of 442
patients, ERB2 protein did not show any correlation with standard
clinicopathological markers except for ERa positivity (Honmaet al, 2008).
Saji et al. showed correlation between ERB2 and PgR negative status in 115 ERa+
tumours(Saji et al, 2002). However, no correlation with standard clinicopathological
markers were seen with ERB2 protein in a numberof other studies (Esslimani-Sahla
et al, 2004; Palmieri ef al, 2004; Skliris et al, 2006).
This study was specifically designed to address the potential role of ERB variants in
endocrine-treated breast cancer, with further selection towards post-menopausal
cases (as discussed previously). Although such selection is valuable in studies of
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outcome, it does introduce some bias in comparison to unselected/consecutive
cohorts. Whilst mitigated by the inclusion of a representative proportion of ERa-
cases, it is possible that some differences in association with clinical or biological
parameters is influenced bythe case selection.
5.7.3 ERB2 protein and outcome
Using the Allred cut-off score (selected by using ROC curve), high ERB2 was
associated with better relapse free survival in the whole cohort, and at shorter follow-
up high ERB2 patients had significantly better RFS and BCS. These outcome
associations were not maintained in the ERa positive cohort. It seemsthe correlation
between ERa and ERB2 may bepartly responsible for the outcome associations in
the whole cohort.
In comparing with other studies, as previously discussed, it is important to consider
the case selection and treatment received. This is sometimes difficult as, although
different treatment sub-groups are noted, treatment-specific outcomeresults are not
always given. Other studies which evaluated ERB2 protein only are discussed here.
Sugiura et al. evaluated both ERB2 mRNAandprotein with outcome in a cohort of
150 patients (ER+ and ER-). High ERB2 mRNA wasassociated with better RFS and
OS in both univariate and multivariate analysis. However, high ERB2 protein was
only associated with better RFS in univariate analysis and not for OS (Sugiura efal,
2007). Though Sugiuraet al. study results are concordant with our findings, there are
some subtle differences between this study and ours in terms of patient selection,
treatment received by patients, antibody used and ERB2 positivity rate and so on.
Shaabanet al. evaluated ERB1, ERB2 and ERS protein expression in a cohort of 757
patients (ERa+ and ERa-) and 250 patients received endocrine therapy in this cohort.
High ER62 significantly correlated with disease free survival and overall survival in
the whole cohort, and also predicted response to endocrine therapy. Patients who
were ERa+/ERB2+ had significantly better overall survival than others. Considering
ER$2 immunostaining alone in our whole cohort, the results presented here are
superficially similar to those seen by Shaabanef al. (Shaaban et al, 2008) in their
larger cohort. For these results to have clinical significance in endocrine treated
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breast cancer we would hope that the associations with outcome would hold true for
the ERa+ tamoxifen-treated cohort, but it was not clear whether this was the case.
Honmaet al. examined ERB1 and ERB2 protein in 442 breast cancer patients (377
ERa+ and 65 unknown hormone status) who received adjuvant tamoxifen
monotherapy and found ERB1 expression was the strongest marker for disease free
and overall survival. However, high ERB2 expression also showedbetter disease free
survival (P=0.03) and overall survival (P=0.038) in Kaplan Meier survival analysis
(Honmaet al, 2008).
5.7.4 ERB2 protein and mRNAcorrelation
Associations between high levels of ERB2 protein (immunoscore) or MRNA (qRT-
PCR) and improved outcome have been seen, but only the qRT-PCR results are
statistically significant in the clinically relevant ERo+ cohort. It is therefore
important to establish the relationship between mRNAandprotein levels in clinical
samples. Notably, many previous mRNA studies made conclusions regarding
biological or clinical relevance based on the presumption that level of protein
correlates with that of mRNA.
Some studies compared the ERB mRNAexpression levels with the ERB protein.
Shaw et al. found no correlation in 37 out of 61 cancers for total ERB (Shaw ef al,
2002). Omoto ef al. also found that ERB1 protein expression was not directly
proportional to mRNA level (Omoto ef al, 2002). A similar lack of correlation was
seen previously for ERB1 using semi-quantitative analysis of ERB1 mRNA in an
overlapping cohort (O'Neill et al, 2004); this was re-confirmed in 82 patients using
quantitative ERB1 mRNA measurement from this study [Pearson (%+) 0.02 P = 0.87;
Spearman (Allred) 0.03 P = 0.83]. This lack of correlation again raises the role of
translational control, protein stabilisation and heterogeneous sample for RNA
extraction skewing the mRNAlevel.
In this cohort of breast cancers there was no evidence of a significant relationship
between ERB2 mRNA andprotein as a whole. The disparity between protein and
RNA expression for ERB2 is even suggestive of an inverse relationship in a
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proportion of cases in the current study. However, in a Japanese study, in a cohort of
150 patients (ERa+ and ERa-cases) ERB1 and ERB2 qRT-PCR significantly
correlated with ERBland ERB2 protein, respectively (Sugiura et al, 2007). A rabbit
polyclonal antibody raised against ERB2 specific epitope was used in this study and
Allred score above 3 was usedas a cut off for positivity (Sugiura ef al, 2007). The
study by Sugiura ef al. contradicts all the other studies published so far, at the same
time it is encouraging, as we know breast cancer phenotype seemsto be different in
various ethnic and geographical regions and whether these phenotypic differences
play a rolein translational controlis an interesting thought.
Due to tissue heterogeneity, any mRNA analysis of tissue homogenates without
selection can contribute to discordance with immunostaining results that are scored
on specific cell types. In contrast to mRNA estimation, protein evaluation by
immunohistochemistry looks into epithelial cells only. Tissue heterogeneity in terms
of amount of tumour and connective tissue in the specimen used to prepare may
influence the amount of specific mRNAs in each sample. To reduce this bias, the
cases were selected for RNA analysis following independent histological review of
adjacent sections, so as to avoid high levels of tissue heterogeneity. Samples from all
cases consisted of at least 75% tumour cells and 67% of cases had at least 90%
tumourcells. Inflammatory infiltrates were present in a minority of cases (at 10% in
15 cases and at 25% in 4 cases). During mRNAandprotein correlation, whether or
not these 19 cases were excluded, they did not unduly influencethe correlation.
The recent study by Cummingsef al. comparing the expression of ERB1, ERB2 and
ERBS mRNAsin whole tumour tissue, and in micro-dissected epithelial cells and
stromalcells obtained from 25 breast tumours have shown greater gene expression in
whole tissue compared to micro-dissected material. Interestingly variants were
differentially expressed in different cell population with ERB1 was significantly
more in stromal cells and ERB5 wassignificantly highly expressed in the epithelium
and ERB2 waslowin both cell types. Again in three individual tumours depending
upon the cellular composition the variants were differentially expressed suggesting
phenotypic differences in tissue composition (Cummingsef al, 2009).
A further consideration when comparing RNA andprotein level is the possibility of
discordance arising from sampling of different areas of the tumour. In the same way
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that protein expression is not homogeneous, mRNA levels may vary between the
sample used for RNA analysis and that used for protein analysis. Hence, use of
different areas of the tumour for mRNA and protein measurement can also effect
correlations seen. That not all mRNAsare translated into protein and different
proteins can have different stabilities and this makes like to like comparison between
mRNAand protein expression difficult. However, good correlation between ERa
mRNAandprotein was seenin this study.
A major factor in the discordance is that many cases express high levels of protein,
but low mRNAlevels; a situation that is not likely to arise from expression ofmRNA
in non-tumourcells. It is however possible that heterogeneity of expression in the
different parts of the tumour specimen used for mRNA and protein analysis
contributes to the lack of correlation and in situ analysis of mRNA and protein in
adjacent tissue slices might addressthis.
That correlation between ERa mRNA and protein was seen in this cohort does
support the notion that sample selection for RNA has been effective, but it must be
noted that the situation for ERa is somewhatdifferent as it is generally not expressed
in the types of cells that might contribute to the samples used for RNAextraction.
Although ERB2 protein levels are apparently not directly related to mRNA levels,
that does not mean that ERB2 protein expression is not related to mRNAlevels in
some cases, or that expression of ERB2 protein is not important in cases with high
ERB$2 mRNA(associated with better outcome). A significant proportion of cancers
(35%) had both high protein and high mRNAlevels and these had a significantly
better outcome than the remaining cases, with cases where both mRNAandprotein
were low having the worst outcome. This good outcome observed for those cases
assessed as having both high mRNA and protein levels was independent in
multivariate analysis.
This suggests that transcription of ERB2 mRNA drives ERB2 protein levels in some
cases, and these cases do particularly well on tamoxifen treatment. It is possible
therefore that the relatively poor utility of ERf$2 protein assessment by
immunostaining as a measure of outcome prediction may be due to high levels of
ERB2 protein in some cases (with lower levels of ERB2 mRNA) being related to
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some form of protein stabilization, or detection of inactive ERB2. It is therefore
perhaps unsurprising that previous studies of ERB2 protein expression did not find
significant associations between ERB2 and outcome in ERa+ tamoxifen treated cases
as these did not include concomitant mRNA measurement. They were thus unable to
distinguish between ERB2 protein associated with increased transcription and that
possibly present due to some form of post-transcriptional control (or perhaps the
breakdown of normalcontrol).
Table 5.1 Frequency of Allred score in breast cancer samples.
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Whole cohort n=141  qRT-PCR cohort n=100
Allred score
cases (%)
No of cases Percentage of No of cases Percentage of
cases (%)
0 2
3 3
4 9
5 27
6 39
‘ 61
1.4
2.1
6.4
19.1
27.7
43.3
15
30
49
15
30
49
 
Table 5.2 Association between ERB2 mRNAandprotein using optimal cut-points
from survival analysis.
 
ERB2 mRNAhigh mRNAlow Total
Protein high 35 44 79
Protein low 14 7 21
Total 49 51 100
 Pearson Chi-square 3.32 P=0.068
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Magnification: A-H & J x20; 1 & K x40   
Figure 5.1 Immunohistochemical staining for ERB2. Breast carcinomas showing
different levels of staining; examples of Allred score 0 (A), 3 (B), 4 (C), 5 (D), 6 (E),
7 (F) and 8 (G).
H-K are low (H,J) andhigh (I, K) magnification images of the same tumour stained
normally (H, I) and following blocking with synthetic peptide (J, K).
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Figure 5.2 Kaplan Meier survival plots RFS (A) and BCS (B) for ER2 protein
dichotomized by high and low Allred score in the whole cohort. High ERB2 protein
level was associated with good outcomein the whole cohort.
Greenline — high protein; Blue line — low protein
Crosseson the lines represent censored data.
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Figure 5.3 Kaplan Meier survival plots RFS (A) and BCS (B) for ERB2 protein
dichotomized by high and low Allred score in the ERa+ tamoxifen cohort. ERB2
protein level was not associated with outcomein the ERa+ tamoxifen cohort.
Greenline — high protein; Blue line — low protein
Crosses on the lines represent censored data.
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Figure 5.4 Kaplan Meier survival plots RFS (A) and BCS (B) for ERB2 by
categorizing the whole cohort into four categories. Cases expressing high levels of
both mRNAand protein had better outcome followed by cases expressing higher
levels of either.
Crosses on thelines represent censored data.
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Figure 5.5 Kaplan Meier survival plots RFS (A) and BCS (B) for cases with both
high ERB2 protein and mRNA Vsother cases in the whole cohort. Cases expressing
high levels of both were associated with better outcome.
Green line — high protein and mRNA;Blueline — high protein and low mRNA/low protein
and high mRNA/both low
Crossesonthe lines represent censored data.
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Figure 5.6 Kaplan Meier survival plots RFS (A) and BCS (B) for cases with both
high ERB2 protein and mRNA Vs other cases in the ERa+ tamoxifen cohort. Cases
expressing high levels of both were associated with better outcome.
Green line — high protein and high mRNA; Blue line — high protein and low mRNA/low
protein and high mRNA/both low
Crosses on the lines represent censored data.
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CHAPTER 6 FINAL DISCUSSION AND CONCLUSIONS
6.1 Final discussion
There have been numerousstudies to date that attempt to address the potential
importance of ERB assessment in breast cancer management. Manyof these studies
make use of mRNAlevels as a surrogate marker for ERB expression, despite the fact
that few have attempted to relate mRNA to protein levels. Other studies do not
address the expression of ERB isoforms, but use techniques that rely on detection of
N-terminal protein or mRNA sequences that are shared by most variants. A good
proportion of studies also fail to take into account menopausal status, stage of the
disease or the treatment given. This study therefore set out to quantitate the
expression levels of ERB wild-type (ERB1) and variant (ERB2, ERB5, ERBA3,
ERBAS) mRNA together with protein expression for ERB2 and address their
relationship to patient survival in a treatment-specific cohort of postmenopausal
womenreceiving adjuvant endocrine treatment but not chemotherapy.
That this retrospective cohort includes a proportion of ERa- cases (30%), similar to
the general breast cancer population, allows reasonable assessment of ERB isoform
expression in relation to other clinical and histological parameters. ERa- cases
afforded some insight into expression of ERBS and exon-deleted variants, but were
excluded in the important assessment of outcome for endocrine treatment, which was
limited to ERa+ cases, reflecting current breast cancer management. Despite this
subgroup analysis, the cohort studied was of significant power to detect outcome-
related associations for previously validated markers (e.g. grade, nodal status, PgR
status) and ER§ variants.
ERBSis similar to ERB2 in structure and the alternative C-terminal exons for these
proteins overlap. ERB5 mRNA levels are similar to and correlate with ER®2 in
ERa-+cases and this is reflected in similar associations with improved outcome.
There has been somerecentinterest in the potential role of ERB1 and ERB5 isoforms
in ERa- breast cancers to act as targets for chemopreventative drugs (Poola ef al,
2005b). Wefind that protein levels of ERB1 and ERB2 are significantly expressed in
ERa- cases, but with no clear relationship to outcome. Both ERB2 and ERB5
114
mRNAs were present in greater amounts than ERB1 in ERa- tumors, but, unlike
ERB2 and ERB1, ERBS mRNAlevels were higher in ERa- cases than ERa+ cases.
These results indicate some differences in regulation of these isoforms that might
have some consequence for breast cancer. We found an association of high ERB5
mRNAlevels with better outcome in our cohort of endocrine-treated ERa- cases,
with no such relationship for ERB1 or ERB2 mRNA. Despite the relatively small
numberof cases, we were also able to demonstrate that ERB5 wasrelated to better
outcomeindependentof nodal status in the ERa- subgroup. This potentially indicates
that cases with high ER®5 are more likely to benefit from endocrine treatment.
However, whether the better outcome of ERa- cases with high ERB5 is related to
their treatment with tamoxifen is unclear and further studies will be required. Given
that protein and mRNAlevels of ERB isoforms do not seem to be directly related, it
remains to be seen if ERB5 protein plays a significant role in ERa- breast disease. In
the recent study by Shaabaner al., ERB5 protein expression significantly correlated
with outcome in cohort of 757 patients obtained from consecutive cases enrolled to
the Nottingham Tenovusprimary breast carcinomaseries over a period of 12 years
(Shaabanet al, 2008).
ERBAS5can act as a dominant-negative isoform of both ERa and ERB (Inoueef al,
2000). As ERa, expression is an indicator of good prognostic outcome and predictive
of tamoxifen benefit, the naturally occurring dominant-negative ERBAS could
suppress the beneficial effects of ERa expression and contribute to tumor
progression. Detectable levels of ERBAS were predominantly found in cancers which
were ERa-, of high grade and highly proliferative; ERBAS wasalso associated with
p53 mutation. Although the low levels and restricted incidence of such variants may
preclude any clear role in behavior of breast cancer (especially in ERa+ tamoxifen-
treated cancers), it would beinteresting to clarify if splicing leading to exon deletion
is more prevalent in more aggressive forms of cancer. This may be a gene-specific
effect, which would point towards a functional role for these ERB splice variants, or
a consequence of more widespread error-prone splicing. Of note both cases
harbouring exon 3 deletion also expressed the exon 5 deleted ERB, suggesting that
the latter may be the case in some cancers. Any functional role for ERB exon
115
deletion variants would presumably rely on expression of the equivalent protein
variant, which has yet to be demonstrated.
Previous assessments of the role of ERB2 (also known as ERfcx) in breast cancer
outcome have been limited. One previous study of 50 ERo positive cases using
immunostaining with a different antibody raised to the same ERB2-specific epitope
(Esslimani-Sahla et al, 2004) failed to show anypredictive association with adjuvant
tamoxifen treatment. Howeverthis analysis was based on detecting differences in
staining between “sensitive” and “resistant” cases using the crude measure ofrelapse
within 5 years of tamoxifen therapy. Unpublished observations (Saji et al, 2005)
similarly failed to show any predictive value in an adjuvant setting. However, an
association of ERB2 protein with a favorable outcome has been seen in a metastatic
and locally advanced setting (Palmieri et al, 2004). Our own previous data (Davies ef
al, 2004) was based on a semi-quantitative RTPCR analysis using an assay in which
ERB5 is co-amplified with ER®2 and distinguished based on size of the PCR
product, similar to the triple-primer assay used elsewhere (Iwao ef al, 2000; Leygue
et al, 1999). Here the results have been confirmed using independent cDNA
synthesis reactions and different splice variant specific PCR conditions. The fully
quantitative nature of the qRT-PCR results allows comparison of mRNA levels
between different variants or of variant levels between tumors, but necessitated
selection of optimal cut points (in this case using ROC analysis) for the
dichotomization required for standard outcome analysis with Kaplan Meierplots.It
should be noted that, whilst such dichotomization is useful in demonstrating
associations with outcome,true utility of ERB variant mRNA measurementwill only
be demonstrated with larger patient cohorts and may bebetter achieved by treating
mRNA quantitation as a continuous variable, as in other RT-PCR based outcome
predictors (Paik et al, 2004).
Our findings indicate that determination of ERB isoform mRNAs(in particular
ERB2) may be useful in delineating ERa+ cases that respond well to adjuvant
tamoxifen treatment. In node negative cases, where the need for additional markers
of response is greatest, our study shows that low ERB2 mRNA levels are
significantly related to worse outcome. However, ERB2 protein levels are apparently
not directly related to mRNA levels and ER#2 protein staining of breast cancer
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sections does not relate to outcome for ERa+ cases. Rather there is some association
of ERB2 immunostaining with better outcome in broader cohorts of patients
(including ERa- cases), due in part to a correlation between ERa and ERP2 protein
levels. A similar lack of association between ERB2 immunostaining and outcomehas
been demonstrated in the neo-adjuvant setting (Miller et al, 2006). In this regard our
result is concordant with Sugiura et al. who examined ERB1 and ERB2 in 150
patients (both ER+ and ER-) who had either no adjuvant treatment or some form of
adjuvant treatment. They found correlation between ERB1 mRNA and protein as
well as ERB2 mRNA andprotein. In univariate Kaplan Meier survival analysis,
higher levels of either protein or mRNA of ERB1 and ERB2 were associated with
better outcome. However, in multivariate analysis only ERB2 mRNA was an
independent marker of RFS or OS (Sugiura et al, 2007). There are some differences
between this study and our own. The antibody used in their study was even though
raised against the same epitope as ours it was rabbit polyclonal antibody and the
ERP2 positivity rate in the cut off used for survival analysis was only 51% compared
to 71% in our cohort. There were also differences in the ethnicity of the population
studied and the treatment received bythe patients.
As previously discussed, Shaabanet al. (Shaaban et al, 2008) evaluated ERB1, ERB2
and ER§5 protein expression in a large retrospective cohort (757 patients) containing
both ERa+ and ERa- patients, treated with various adjuvant therapies. High ERB2
significantly correlated with better outcome in the whole cohort, and also predicted
response to endocrine therapy. This was somewhat similar to our outcome with
ERB2 in the whole cohort of 141 patients, but this association with outcome waslost
whenthe analysis was limited to ERa positive tamoxifen treated patients. It was not
clear whether this subgroup analysis was performed in Shaaban ef al. cohort. More
recently, Honma ef al. examined ERB1 and ERf2 protein in 442 breast cancer
patients (364 ER+ & 78 ER-) who received adjuvant tamoxifen monotherapy. Both
ERB1 and ERf2 protein expression showed better disease free survival and overall
survival in KM univariate analysis. However, ERB1 expression was the strongest
marker for both disease free and overall survival in further analysis (Honmaetal,
2008).
That expression of ER®2 protein may be important is demonstrated by the good
outcome in those cases assessed as having both high mRNAandprotein levels and
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the independentstatus of these markers in multivariate analysis. It would seem thatat
least in those cases wheretranscription of ERB2 mRNA drives ERB2protein, these
cases do particularly well on tamoxifen treatment. Conversely, where ERB2 levels
are depleted both in terms of mRNA and protein, this is associated with worse
outcome. The complication arises in the apparent expression ofrelatively high levels
of ERB2 protein in somecases that cannot be explained by transcriptional control. It
is possible therefore that the relatively poor utility of ERB2 protein assessment by
immunostaining as a measure of outcome prediction in post-menopausal, ERa+,
tamoxifen-treated breast cancer may be due to high levels of ERB2 protein in some
cases being related to some form ofprotein stabilization. One explanation for these
cases having a poorer outcome, than those in which mRNAanprotein are both high,
would be that the protein is stabilised and does notfulfil the apparently protective
role of ERB2. Shaaban et al. has shown cytoplasmic expression of ER2 protein is
related to poor outcome. Given that the cytoplasm is the normal route for
degradation; might this cytoplasmic staining be related to a failure to degrade
abnormal ERf2? It is currently unclear if those cases with cytoplasmic staining are
the same onesthat have high levels of ERB2 nuclear protein but low levels of ERB2
mRNA.
Whilst our data would suggest that ERB2 could contribute to an improved outcome
in a subgroup ofpatients, it provides further evidence that determination of ERB2
protein by immunostainingis unlikely to provide the predictivetest that is needed for
better targeting of additional therapy in those women for whom tamoxifen is not
likely to be sufficient. The failure to link protein expression to outcome measures
does not preclude the use of ERB2 mRNAin clinical setting. That mRNA
measurement (e.g. by qRT-PCR) remains largely outside the remit of clinical
laboratories has historically been due largely to technical constraints, although with
the advent of tests such as Oncotype DX this is now being addressed (Paik ef al,
2004). More important is the need for larger trials to validate any such markers (be
they RNA or protein based). Such trials should, as here, be based on specific
treatments. With the increased useofalternative adjuvant endocrine therapies such as
aromatase inhibitors, it will be worthwhile re-investigating the predictive power of
ERf2 and ERPS in other treatment-based cohorts.
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6.2 Conclusions
This study was unique in that mRNAsofindividual splice variants were measured in
a clinically-relevant, treatment-specific cohort with concomitant ERB2 protein
expression. Irrespective of the clinical utility of any ERB based measurement, the
data presented here clearly implicates different roles for ERB splice variants in the
behaviour of breast cancer, both in terms of associations with clinicopathological
characteristics and with treatment-specific outcome. Hence the data support the
hypothesis that particular variants of ERB may be more closely associated with
outcome following adjuvant tamoxifen treatment of breast cancers. It remains
unclear if such variants are useful as predictive markers. Nevertheless they offer
further insight in to the complex molecular landscape of breast cancer.
Interventional studies will be required to confirm if this role is important, or if ERB
variant levels merely act as surrogate markers for other control pathways.
The differential expression pattern seen for the alternatively spliced variants
indicates a complex level of control at the transcriptional and splicing level in breast
cancers. Differential expression of C-terminal variants was also seen in various
normaltissues, together with our results, splicing control is most likely functionally
important. However, the low levels of deletion variants and association of ERBAS
with more aggressive, largely ERa- cancers are potentially related to aberrant
splicing.
Disassociations between protein and mRNAlevels can be partly explained by tissue
heterogeneity (Cummingsef al, 2009), howeverit supports an important modulating
role for translational control (Smith et a/, 2010) and hint at subset of tumours in
which ERB2 protein may be stabilised. Associations of ERB2 protein with better
outcome were found, but only in the wider cohort and may in part be due to a
correlation with ERa expression.
6.3 Future directions
Ourstudy and recent larger studies (Shaaban ef al, 2008; Honmaet al, 2008; Sugiura
et al, 2007) have shown association between wild-type ERB1 and ERB2 andbreast
cancer outcome. The general consensusis that high ERB2 expression is associated
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with better outcome. However, further larger studies with standardized protocols are
needed before these results can be translated to tests to be used in clinical practice.
It would be interesting to see whether ERB1 and ER$2 protein can be measured
retrospectively from previoustrials like ATAC and BIG 1-98. Although conclusions
would be limited by the case selection used for these trials, they provide large
clinically relevant cohorts, at least some of which are available as tissue microarrays
through the TransATACstudy. This will also provide an opportunity to evaluate the
role of ERf in relation to aromataseinhibitors.
There is also a need to include ERB immunostaining in future prospective studies
with other potential markers, which will eventually pave a way towardsclinical
utility in breast cancer management. As for drug treatments, prospective trials are
widely considered to be important to validate biomarkers. The practical aspects of
prospective studies (such as the case-by-case assessment of markers alongside
clinical care) more closely mirror intended use (compared to processing and
assessmentof large retrospective cohorts).
ERB2 mRNAcould be added to other mRNA basedstudies like Oncotype DX to see
whetherit will add to the value to their results. This may not be very feasible in the
short term, as this test is centralized and subject to a numberofpatent and licensing
issues as well as regulatory approval, but could be considered if a reassessment of
markers was conducted. There are also more practical issues, such as validating the
measurement of ERB2 qRTPCRfrom paraffin embeddedtissue and positioningthis
additional markerin the risk score formula.
Further functional studies are needed to examine the role of ERB in breast
carcinogenesis. With the discovery of co-regulator proteins which play an important
role in ER signalling it will be interesting to see how they can beutilized in clinical
practice to increasethe efficacy ofthe selective oestrogen receptor modulators. The
importance of the binding of these co-regulators to ERB will need to be considered
whenassessing ERa function.
It might be useful to study the association between ERB and other established
markers like PgR and HER2 to understand the interaction between these pathways.
For example, there is interplay between ERa and growth factor pathways through
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phosphorylation of this ER at different sites. Further work along similar lines with
ERBisoforms might help explain some aspectsoftheir biology.
On a more general point, the work here has shown that measurement of ERB splicing
variants (be they isoforms or aberrant mRNAproducts) has someutility. More recent
technologies, such as microarrays that measure multiple splicing events and
extremely high throughput RNA sequencing on “next generation sequencing”
platforms, allow us to study such events on a wider scale. These could be used to
address if differences in splicing events seen are specific to these pathwaysor are
part of a wider deregulation of splicing associated with cancer phenotype.
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